VANCOUVER, BRITISH COLUMBIA–(Marketwire – Dec. 8, 2010) – ALDA Pharmaceuticals Corp. (TSX VENTURE:APH)(OTCQB:APCSF) (the “Company” or “ALDA”) announces that it is undertaking a non-brokered private placement of up 2,000,000 units of the Company (the “Units”) at a price of $0.10 per Unit for proceeds to the Company of up to $200,000. Each Unit will consist of one common share of ALDA and one non-transferable share purchase warrant entitling the holder to acquire one additional common share of ALDA at a price of $0.20 per common share for a period of 24 months from the date of the issuance of the purchase warrant with a forced exercise provision attached to each warrant commencing on the day following the expiry of any applicable hold period on the underlying Common Share, stating that if, for ten consecutive trading days, the closing price of the listed shares of the Company exceeds $0.40 then the exercise period of the warrants will be reduced to a period of 10 days following such trading days.

Certain insiders of the Company have been selling common shares of ALDA through the facilities of the TSX Venture Exchange in connection with this private placement and will reinvest up to $175,000 of the proceeds in the private placement. Accordingly, insiders of ALDA will be subscribing for over 25% of the offering, constituting a related party transaction pursuant to Multilateral Instrument 61-101 and TSX Venture Exchange Policy 5.9 which is exempt from the requirement to obtain an independent valuation pursuant to Section 5.5(b) of MI 61-101 and the requirement to obtain minority shareholder approval pursuant to Section 5.7(1)(b) of MI 61-101.

The offering is being made on a private placement basis pursuant to registration and prospectus exemptions of applicable securities laws and is subject to acceptance by the TSX Venture Exchange. All securities issued will be subject to a four month restricted period and will bear a restrictive legend accordingly. Net proceeds from the offering will be used for working capital purposes.

About ALDA Pharmaceuticals Corp.

ALDA is focused on the development of infection-control therapeutics derived from its patented T³6^® technology. The company trades on the TSX Venture Exchange under the symbol APH and on the OTCQB under the symbol APCSF. The Company was the Official Supplier to the Vancouver 2010 Olympic Winter Games and the Vancouver 2010 Paralympic Winter Games and is the Official Supplier to the Canadian Olympic Committee, the 2010 Canadian Olympic Team and the 2012 Canadian Olympic Team for antiseptic hand sanitizer, disinfectant and disinfectant cleaning products. The Company was also selected as one of the TSX Venture 50 companies in the Technology and Life Sciences sector for 2010.

Terrance G. Owen, Ph.D., MBA, President & CEO

ALDA Pharmaceuticals Corp.

The Units, common shares, warrants and the common shares issuable upon exercise of the warrants have not been registered under the United States Securities Act of 1933 (the “Act”) and may not be offered or sold absent registration under the Act or an applicable exemption from the registration requirements thereof. This news release does not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction or an exemption therefrom.

Cautionary Note Regarding Forward-looking Statements: Information in this press release that involves ALDA’s expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. ALDA generally uses words such as “outlook”, “will”, “could”, “would”, “might”, “remains”, “to be”, “plans”, “believes”, “may”, “expects”, “intends”, “anticipates”, “estimate”, “future”, “plan”, “positioned”, “potential”, “project”, “remain”, “scheduled”, “set to”, “subject to”, “upcoming”, and similar expressions to help identify forward-looking statements. The forward-looking statements in this release are based upon information available to ALDA as of the date of this release, and ALDA assumes no obligation to update any such forward-looking statements. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of ALDA and are subject to risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations.

CHICAGO, IL–(Marketwire – December 8, 2010) – Marketwire announces that the following releases were included in the Health/Fitness/Wellness Features Package. Below is the list of headlines included in the package.

EmpowHER Offers Resources to Help Women Manage Holiday Stress
http://www.marketwire.com/press-release/EmpowHER-1365614.html

Marketwire’s Media Relations Department serves the information needs of the media. As a liaison between the media and Marketwire clients, our Media Relations team utilizes a variety of means to ensure that journalists, analysts and online communities receive news and information on companies, industries and topics of interest in the formats and via the distribution mechanisms they desire. To that end, our Media Relations staff, located throughout North America, the UK and Asia, manages relationships with media around the world, specializing efforts across 140 vertical industries, traditional and specialty markets, and various media.

HOUSTON, TX–(Marketwire – December 8, 2010) –  Plunkett Research, Ltd. has released its newest market research and competitive analysis report, Plunkett’s Health Care Industry Almanac, 2011 edition, which identifies and analyzes major trends shaping the health care industry.

According to Jack W. Plunkett, CEO of Plunkett Research, Ltd., “While total health expenditures continue to grow in the U.S., health care is spreading rapidly in emerging nations like India and China.”

Major trends affecting the Health Care Industry analyzed in Plunkett’s report include:

• Continued rise in health care costs.
• Employers push health care costs onto employees.
• Medicare and Medicaid spending continue to surge.
• Health Care Reform Act of 2010 set to bring big changes.
• Major drug patents expire while generic growth continues.
• Quality of care and health care outcomes data become available online.
• Obesity sparks government action.
• Health care thrives offshore, medical tourism grows.
• Disease management programs take root.
• Health care industry to grow rapidly in China and India.

“Eventually, innovative health practices and technologies developed for lower-income nations will migrate to the U.S., helping to contain costs,” said Jack Plunkett.

A complete report with detailed industry trends and statistics analysis is provided in Plunkett’s Health Care Industry Almanac, 2011 edition. This informative reference book gives you the competitive intelligence you need, with a detailed industry overview, industry analysis and market research. Plus, thousands of contacts for business and industry leaders, industry associations and industry sites, as well as statistical tables, an industry glossary and thorough indexes — everything you need all in one value-priced, easy-to-use package.

A complimentary video of Plunkett discussing these trends is now available on the Plunkett Research website, as well as YouTube, and an Introduction to the Health Care Industry can be viewed at Plunkett’s website. 

About Plunkett Research, Ltd.
Plunkett Research is a leading provider of industry trends analysis and market research. Our reports and data services are used by the world’s top corporations, consultants, universities, libraries and government agencies. Plunkett’s products save time and effort when you need competitive intelligence, market research or marketing data. For more from Plunkett Research, become a Fan on Facebook and subscribe to our YouTube channel.

Click here to see all recent news from this company

NEW YORK, NY–(Marketwire – December 8, 2010) – Labs using DNA sequencers are more concerned with accuracy than cost in future purchases, according to a survey conducted by Kalorama Information. The healthcare market research publisher reported the survey findings in its recent report, “DNA Sequencing Market Trends (Kalorama Survey of Labs Using Next-Gen and Capillary Systems).”

“A significant number of respondents chose accuracy over cost, ease-of-use or speed,” said Justin Saeks, Kalorama Information’s biotech analyst and author of the report. “This was true both for labs using first-gen or next-gen systems.”

The Kalorama Information survey of 120 laboratories using next-gen and capillary systems was carried out from July to September of 2010, with the majority in the latter portion. About 70% of the labs were academic; the remainders were hospital, government or independent labs. 70% of the hospitals were in North America, 12% in Europe and 18% in ROW. The bulk of respondents were core labs with more than a third doing contract work. Respondents were asked for the most important criteria in considering a new sequencer purchase. Accuracy rated highest for 78.8% of respondents. Cost per sample run was also important, rating second as a criterion with 63.6% of respondents. 

Kalorama Information found that the preference for accuracy occurred regardless of whether the survey respondent used a 454, SOLID, Illumina or Capillary System. Saeks, who has been analyzing sequencer markets for the past decade, was not surprised at the ranking of accuracy over other qualities in purchasing new sequencers.

“One of the things we heard from respondents was that accuracy is proportionately more important because in sequencing the margin of error is low,” said Saeks. “Even a .01% error rate adds up to a lot. And accuracy drives other areas — a clean sequence, for instance, will enable software algorithms to work well.”

Kalorama Information has been covering developments in the DNA sequencing markets since 2007. More information on this report, “DNA Sequencing Market Trends (Kalorama Survey of Labs Using Next-Gen and Capillary Systems),” can be found at: http://www.kaloramainformation.com/redirect.asp?progid=80130&productid=2657156.

About Kalorama Information
Kalorama Information supplies the latest in independent market research in the life sciences, as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on Twitter (http://www.twitter.com/KaloramaInfo) and LinkedIn (http://www.linkedin.com/groups?gid=2177845&trk=hb_side_g).

Click here to see all recent news from this company

RICHARDSON, TX–(Marketwire – December 8, 2010) – KBM Group, the global leader in knowledge-based marketing solutions, has agreed to acquire Marketing Direct, Inc. (MDI), the leading provider of agency services to the healthcare industry. MDI is an integrated marketing services company with expertise in strategy, design and execution of marketing campaigns, from go-to-market strategies and sales-lead conversion to media placement, primarily for the healthcare industry. The acquisition strengthens and broadens KBM Group’s existing products and services for the healthcare market, augmenting the company’s core capabilities with a wide array of agency services such as creative and media placement, including digital media channels. Based in St. Louis, MO, MDI is a privately held company. Financial terms of the deal are not being disclosed, and the acquisition is subject to regulatory and shareholder approvals.

Founded in 1997, MDI has been ranked one of America’s fastest-growing private companies by Inc. Magazine in its annual Inc. 5000 survey for 2008, 2009 and 2010. The company’s growth has been driven by providing direct and interactive marketing services primarily to the healthcare industry, but the company has experience in retail and financial services as well. MDI’s capabilities span marketing services end-to-end, including: consulting services, developing and optimizing direct market channels, facilitating the sales process through sales force automation, determining the best mix of online and offline media, performing analytics and testing to ensure results, developing creative campaigns from messages to branding, optimizing websites and online strategies, and media placement and execution. Providing these multichannel marketing services to targeted industries has given MDI industry-specific expertise that has allowed it to help its clients acquire millions of customers and engage them to improve healthcare outcomes.

With the combined strength of the acquisition, KBM Group is also officially announcing the launch of KBM Group: Health Services, a new business practice focused on improving how companies across the healthcare continuum engage with consumers and healthcare professionals. KBM Group: Health Services will immediately intensify its focus on helping organizations within the healthcare ecosystem create more meaningful engagements with consumers for the ultimate goal of improving healthcare outcomes while reducing the overall cost of healthcare services. Dennis Barnes, Jr., President & CEO of MDI, will become President, KBM Group: Health Services. The new unit will remain part of Enterprise Services within KBM Group.

“While KBM Group and MDI have been recognized and established leaders within healthcare for several years now, current and impending changes to healthcare require a more holistic approach to multi-channel engagement if we are to substantially reduce costs while improving outcomes,” says Dennis Kooker, KBM Group’s President & COO for Enterprise Services. “Combining KBM Group’s industry standards for data, analytics, and database services delivered through its Consumer Healthcare Engagement Platform (CHEP) with MDI’s expertise in blending creative content and program design with analytics was an obvious combination. MDI has also invested heavily within innovative digital channels that mark the future of consumer engagement. The fundamental beliefs of our organizations and how to serve the healthcare ecosystem are very much aligned.”

Dennis Barnes, President & CEO of MDI, says, “We look forward to contributing our successful record of growth and healthcare expertise to KBM Group, and to integrating our capabilities with KBM Group’s superb data and analytics capability. As an agency specializing in healthcare, we are impressed with the level of healthcare subject matter expertise and the vision that KBM Group has created for the healthcare ecosystem. I am thrilled to have the opportunity to lead an organization with the combined resources and capabilities that KBM Group Health will possess; not to mention how exciting it is to be able to prove our more fundamental goal of driving down the cost of healthcare in this country without needing to make villains out of the healthcare providers.” 

New York-based mergers & acquisition firm AdMedia Partners acted as exclusive financial advisor to MDI in the transaction (www.admediapartners.com). For information about MDI and its transition to KBM Group: Health Services, go to www.marketingdirect.com.

About KBM Group
KBM Group is the global leader in knowledge-based marketing solutions. Expert in both digital and traditional direct marketing, KBM Group helps companies manage, analyze and optimize marketing data to engage more effectively with their customers and prospects. KBM Group’s integrated, world-class solutions include strategic consulting, digital services, database services, analytics, marketing management, response services, data and marketing outsourcing. The company has 16 offices in nine countries serving global, enterprise and B2B2C-focused companies. KBM Group’s parent company, Wunderman is part of Young & Rubicam Brands and a member of WPP (NASDAQ: WPPGY). www.kbmg.com.

Click here to see all recent news from this company

DENVER, CO–(Marketwire – December 8, 2010) – Like the scale in the doctor’s office, the numbers can be daunting. Similarly, the statistics that reveal an increasingly overweight America — 67 percent and rising — are sending shivers down the spine of this nation’s health care system, especially in corporate America where the costs of keeping employees healthy are threatening both the bottom line and the country’s economic future.

Today it costs employers an estimated $13,000 annually to provide premium health care benefits for a typical employee and his or her dependents, and that figure has gone up 10 percent each year for the past decade. Of that annual amount, almost $10,000 is paid by the employer. 

In an attempt to stem the tide, Denver-based incentaHEALTH has focused on one of the biggest drivers of health care costs: obesity. Overweight and obese employees incur over $1,500 in additional costs for the employer each year. In response, incentaHEALTH has developed a unique program that pays employees and their families to lose weight, stay healthy and remain productive. Blending technology, ingenuity, medical expertise, and employer resources, it is designed to encourage greater participation by employees in typical company health plans.

According to Todd McGuire, Chief Technology Officer, who co-founded the company in 2002 with CEO Jack Rule, the idea for incentaHEALTH was developed after discovering that among the most pressing issues facing the business world at the time were runaway health care costs and obesity.

“In 2002 we weren’t happy with the wellness programs used by the rest of the industry, so we created our own,” McGuire said. “Our technology authenticates health outcomes instead of relying on people to self-report. Since we are paying cash incentives, you don’t want somebody to send a friend down to weigh in for them.”

The centerpiece of the incentaHEALTH system is the patented HEALTHspot kiosk which, when strategically placed throughout a company’s facilities, provides:

• Automated biometric measurements of weight, blood pressure and body mass index (BMI) using authenticated measurements (not self-reported)
• Instant feedback to participants and program administrators
• 24-hour, low cost operation and remote maintenance
• Enhanced privacy
• Full-body digital imaging to keep track of participant progress and create a visual progress report
• Complete and accurate electronic records for both employee and employer

Supporting the kiosks, the program uses a variety of communication tools to reach all employees and motivate them to participate. Says McGuire, “Behavior change is a daily battle. It won’t occur with an occasional newsletter. A better approach is a daily coaching plan using emails and text messages that shows employees and their dependents exactly how to eat and exercise.” The program incorporates onsite kickoff sessions and printed support materials to reach employees without email access.

“The national view of health and wellness has matured significantly since we started our business,” said McGuire. “After extensive research of the problem and conducting surveys of the workforce, the wellness industry has found that people are inactive, overweight, have high blood pressure and are not eating properly. Employers are now demanding programs that result in real behavioral changes to tackle these issues.”

“Historically, employers have offered $50 to employees just to sign up for a wellness program, whether they used it or not,” he added. “What we do is shift from an incentive for participating to an incentive for measured performance. For example, if an employee signs up for our program and achieves a 15 percent weight loss, they will get paid, in actual dollars on a brightly colored check, when they weigh in at the HEALTHspot kiosk every 90 days.” The program pays incentives ranging from $15 to $150 per quarter to all employees based on the amount of weight they lose, so every level of success is rewarded.

So far, the incentaHEALTH approach to corporate wellness is working. Organizations across the globe are signing up — companies like Jackson National Life Insurance Co., Virginia Tech, Kaiser Permanente, Long Beach Memorial Medical Center, Accident Fund Insurance Company of America, U.S. Department of Health and Human Services, and others that are concerned about their employees’ health.

“incentaHEALTH has become an integral part of our overall wellness program, which helps our associates make healthier lifestyle choices,” said Cheng Hsu, benefits manager at Jackson National.

And users are noticing a big difference in their health.

“I’ve lost 70 pounds on this program. I am now eating healthy, watching my portion sizes and exercising,” said one employee participant. “It was a true godsend.”

About incentaHEALTH
incentaHEALTH is an innovative health care technology company based in Denver, Colorado. incentaHEALTH’s fully outsourced, employee weight management program is designed to help organizations reduce their health care costs by offering incentives to employees for improving their health. This is achieved by helping employees manage their weight through the use of interactive email coaching, workplace weigh-ins on private kiosks, and cash rewards for maintaining long term health improvements. For more information, visit www.incentahealth.com.

Click here to see all recent news from this company

TUSTIN, CA–(Marketwire – December 8, 2010) – Radient Pharmaceuticals Corporation (RPC) (NYSE Amex: RPC) today announced it has completed a pilot clinical study to measure the feasibility of using its Onko-Sure® in vitro diagnostic (IVD) cancer test kit as a veterinary tumor marker initially for cancer detection in domestic cats.

Preliminary data from the Onko-Sure® assay pilot study measuring domestic cat serum suggests RPC’s Onko-Sure® IVD cancer test may potentially detect cancer in domestic cats. In this pilot study, RPC ran samples from confirmed normal domestic cats and domestic cats with cancer. For cats with cancer, RPC ran a serum sample obtained first when the cats were cancer-free and another sample subsequently when the cats were confirmed with cancer. The relative levels of Onko-Sure® for the cats were compared using the Onko-Sure assay and showed a 2,853% increase in Onko-Sure levels versus the healthy sample. RPC is currently engaged in full clinical trial including 71 samples, which includes an antigen characterization that involves testing to identify direct evidence that RPC’s Onko-Sure® IVD cancer test kits are effective in cancer detection in domestic felines.

According to Douglas MacLellan, Chairman and CEO of Radient Pharmaceuticals, “This development is anticipated to open the use of our Onko-Sure® assay as a veterinary cancer tool that could play an integral role in the screening and early detection of cancer for veterinary patients and further enhance RPC’s strong portfolio of novel oncology products. This is truly an exciting development for the Company and our valued shareholders.”

Onko?Sure is a simple, non?invasive, patent?pending and regulatory?approved IVD test for use as an aid in early detection of cancer. Onko?Sure enables physicians and their patients to effectively monitor and/or detect certain types of cancers by measuring the accumulation of specific breakdown products in the blood called Fibrin and Fibrinogen Degradation Products (FDP). FDP levels rise dramatically with the progression of cancer. Onko?Sure is approved by the US FDA for the monitoring of colorectal cancer, Health Canada as a lung cancer screen and cancer monitoring tool, and the European Union, Indian government, Korean government, and Taiwanese government as a cancer monitoring or cancer screening test. Onko?Sure test kits are currently sold as a blood test for cancer in Europe, India, Taiwan, Korea, and Vietnam and in Chili for research use.

About Radient Pharmaceuticals:
Headquartered in Tustin, California, Radient Pharmaceuticals is dedicated to saving lives and money for patients and global healthcare systems through the deployment of its FDA-cleared In Vitro Diagnostic Onko-Sure® Test Kits for colon-rectal cancer recurrence monitoring The company’s focus is on the discovery, development and commercialization of unique high-value diagnostic tests that help physicians answer important clinical questions related to early disease-state detection, treatment strategy and the monitoring of disease progression or recurrence. To learn more about our company, people and potentially life-saving cancer test, visit.

Forward-Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company’s operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

Click here to see all recent news from this company

SAN FRANCISCO, CA–(Marketwire – December 8, 2010) – Salesforce.com Dreamforce Conference — Appirio has selected RehabCare as Cloud Pioneer of the Year, an annual award given by Appirio to companies and individuals that demonstrate leadership in cloud computing initiatives and a commitment to moving their business forward using public cloud platforms. 

RehabCare is a leading provider of physical rehabilitation program management services in more than 1,260 hospitals, skilled nursing facilities and other long-term care facilities in the U.S. They own and operate 35 hospitals, employ more than 18,000 people and report $1.6B in revenue. RehabCare’s commitment to using cloud-based and mobile platforms to improve patient care while growing their business and staying ahead of complex healthcare regulations stood out among more than a dozen nominated organizations.

“We view our technology investments as core to our company’s future and critical for patient care, and we think it can be a model for others in this industry,” said Dick Escue, CIO of RehabCare. “Using cloud computing, we can do things now that we wouldn’t have even thought possible two years ago. We see it as a huge differentiator for our company and the care we can provide.”

Over the past year, RehabCare has invested in building out an integrated technology platform that has dramatically improved their patient intake and referral process, the way they track, benchmark and improve rehabilitation procedures, and the way they report and communicate progress to Medicare, patients and their families. RehabCare has standardized on platforms, such as Salesforce, Force.com, Google Apps, and Google Health, and are in the process of developing a comprehensive cloud-based Electronic Medical Record platform that will begin rolling out next year. They’ve armed thousands of therapists with iPhones and iTouches and have been highlighted by Apple for their use of the iPad in healthcare.

Appirio’s Cloud Pioneer awards program was introduced earlier this year to recognize the champions and change agents among Appirio’s customers — those who recognize the unparalleled benefits of public cloud platforms and drive projects that are not only successful but truly impactful for their organization. Each Cloud Pioneer award winner is chosen by Appirio’s leadership team, based on nominations from the company’s delivery managers and cloud architects. Other 2010 Cloud Pioneer award winners include individuals at AIG Edison, Dolby Laboratories, DeVry University, Dunkin Brands, Japan Post Network and Perceptive Software. 

“The recipients of Appirio’s Cloud Pioneer award illustrate the potential of cloud computing to shape business strategy, accelerate innovation and drive competitive advantage,” said Chris Barbin, CEO of Appirio. “The executives and IT team at RehabCare who are applying cloud and mobile technologies throughout their business exemplify every one of these benefits. We are privileged to work with them and all of our Cloud Pioneers.”

Appirio’s 2010 Cloud Pioneers
Dick Escue and Jayson Chitwood (RehabCare), Tohru Futami (AIG Edison Life), Mary Ann Lusk and John Cunningham (DeVry University), Curtis Hodge and Scott Sullivan (Dolby Laboratories), Michael Wordell, Erik Astin, Greg O’Connor and Jon Cohen (Dunkin Brands), Neale Wooten (Perceptive Software), Yoshihiko Ohta (Japan Post Network)

About Appirio
Appirio (www.appirio.com) is a cloud solution provider offering products and professional services that help enterprises accelerate their adoption of cloud applications and platforms. Appirio’s innovation and expertise has been recognized by BusinessWeek as one of America’s Most Promising Startups and by AlwaysOn as 2010 On-Demand Company of the Year. Appirio has helped more than 180 leading enterprises implement, build and manage mission critical cloud solutions using salesforce.com, Google, Workday and Amazon. We are proud to serve a wide range of customers such as Avago, the City of Los Angeles, Diversey, Dunkin Brands, Flextronics, Japan Post Network, Ltd., IMS Health, Motorola, Qualcomm, RehabCare, Safety Kleen, Starbucks and VMware, as well as the 5,000 companies that use Appirio’s products to connect and extend cloud platforms. Founded in 2006, Appirio has offices in the U.S. and Japan, and is backed by Sequoia Capital and GGV Capital.

PRINCETON, NJ–(Marketwire – December 7, 2010) – More employers and insurance companies are providing domestic medical travel incentives such as waived deductibles; coinsurance plans and covered travel expenses if employees will simply travel within the United States for healthcare travel or to another region or city for medical care. “The savings are significant and therefore insurers and third party administrators are partnering with healthcare providers for new revenue sources, especially in these times of reduced revenues thanks to healthcare reform,” said David Goldstein, president of Health Options Worldwide (HOW), an online medical tourism agency that provides high-quality low-cost healthcare options domestically and internationally.

In fact, large employers are negotiating with American hospitals located in other states and encouraging employees to seek healthcare for major illnesses and surgeries in other regions of the country. “Employers are partnering with insurance companies and hospitals to save money on their employee health plans,” said Goldstein. “They are accomplishing this by negotiating single rate packages with high-quality hospitals in other states, to include all fees for medical services in a single treatment program.”

Employers who adopt “domestic medical travel” can reduce healthcare costs 20-40% simply by referring employees to American facilities with higher-quality care and lower negotiated prices than in their own hometown. Health industry analysts believe that medical tourism, and more specifically domestic medical travel, could improve overall quality of care and help drive down costs with national competition.

Healthcare savings in domestic medical travel programs are realized from lower prices, which are negotiated between the company and the out-of-state hospital. Reduced complications from procedures performed at these high-quality hospitals also help the bottom line. Follow-up care is handled at the local hospital and covered as part of the treatment program, under the company’s insurance plan.

“Domestic medical travel is not a new concept as employers and insurers have always referred patients to high-quality facilities elsewhere for complex procedures,” said Goldstein. As healthcare costs continue to rise nationwide, domestic medical travel is a way for major employees to control escalating costs and provide their employees with the best quality care.

Click here to see all recent news from this company

ATLANTA, GA–(Marketwire – December 7, 2010) – Jane Green, PhD, president of Morley Research Consortium, and Donald Johnson, Chief Operations Officer of Opus Institutional Review Board, have been appointed to the India-US Business Network (IUSBN) Board of Directors.

In this capacity Dr. Green and Mr. Johnson will be integral to shaping the relationship between India and the United States as the two countries explore and develop mutually beneficial opportunities. The initial four areas of interest for the IUSBN are Biotech, Pharma, Diagnostic, Devices and Health Care; Cold Chain; Education; and Renewable Energy. 

The two Atlanta leaders, who both have extensive experience in clinical research, have been asked to sit on the Biotech Committee for the IUSBN. This committee is focused on matching companies from each country with counterparts in research and development.

“This is both an honor and an opportunity,” said Dr. Green. “By furthering cooperation with India, we achieve the ability to improve the level of research and development in the area of biotech in both countries. I believe this exchange of ideas and information can create exponential advances in developing products and technologies that will benefit the entire world.”

Dr. Green’s organization, the Morley Research Consortium, assists device and drug companies to achieve their research goals of bringing a new product to market through its contract research organization which additionally provides research compliance, total trial management, contracting, site identification and training.

“India is a world leader in technology innovations, and expects to achieve similar success in the biotech field,” said Mr. Johnson. “I am pleased to be able to play a role in helping reach that goal, while also strengthening and benefiting U.S. companies.”

Mr. Johnson manages Opus Institutional Review Board (IRB), the ethical overview organization mandated to review clinical research studies worldwide. Opus IRB has a board of directors consisting of the country’s top practicing physicians in a variety of clinical specialties and encompasses over 20 medical disciplines.

Mr. Johnson and Dr. Green are the first two board members of the IUSBN from the southern region of the U.S. and they are planning the initial Atlanta area meeting of the IUSBN in the first quarter 2011 for others interested in the organization.

Learn more about IUSBN at www.iusbn.org. 

IRVINE, CA–(Marketwire – December 7, 2010) – SK&A, A Cegedim Company, a leading provider of healthcare information solutions and research, today announced the launch of its new web video series, “My Data Dilemma.” The series will feature SK&A clients from industries such as pharmaceutical, biotechnology, healthcare consulting, medical device and others, discussing their specific marketing challenges and how they overcame them through effective targeting and use of SK&A’s healthcare data products.

Episode one of “My Data Dilemma” takes viewers inside a healthcare consulting company that was challenged with identifying and reaching all U.S. blood bank directors and maternity nurses to execute surveys in support of two campaigns. One of the company’s senior vice presidents identifies the challenge the organization faced, the strategy that was executed with SK&A’s help and the results the company received from the project.

“Video is a great medium to effectively deliver the value and insight of successful marketing strategies and tactics to our large base of clients and prospects, and I am excited the SK&A marketing department has provided an insightful and engaging series that will help our customers learn from one another,” said SK&A’s Dave Escalante, Vice President of Data and Information Solutions. “With healthcare marketing strategies changing so rapidly, we feel it is important to embrace our leadership position in this space, connect our community of users, and promote the exchange of ideas.”

SK&A’s commitment to creating a community within the healthcare marketing industry is reflected in its social media outreach efforts, which span across its blog, LinkedIn, Facebook, Twitter and YouTube. Users can find news articles, discussions and other resources available at SK&A. All of SK&A’s market insight reports, press releases and company announcements can be accessed through these social media channels. The web video series will be posted on SK&A’s website and YouTube, with access from all the social media web pages.

Coming soon in episode two, “My Data Dilemma” cameras visit the office of a global biotech company that was challenged with identifying all the U.S. hospitals that treat a specific disease. Tune in to see how they found a solution for their marketing research challenge.

To view episode one of “My Data Dilemma,” visit http://www.skainfo.com/video_series.php. 

About SK&A, A Cegedim Company:
SK&A is a leading provider of healthcare information solutions and research. SK&A, as part of Cegedim’s global OneKey® offering, researches and maintains contact and profiling information for over two million healthcare practitioners, including 800,000-plus prescribers. SK&A also offers the only 100-percent telephone-verified database of email addresses of U.S. prescribers and professionals working at active healthcare sites. SK&A’s customers include many of America’s most recognized healthcare, life sciences and pharmaceutical companies. Please visit www.skainfo.com for more information or www.skalivecounts.com for counts and ordering.  

About Cegedim:
Founded in 1969, Cegedim is a global technology and services company specializing in the healthcare field. Cegedim supplies services, technological tools, specialized software, data flow management services and databases. Its offerings are targeted notably at healthcare industries, life sciences companies, healthcare professionals and insurance companies. The world leader in life sciences CRM, Cegedim is also one of the leading suppliers of strategic healthcare industry data. Cegedim employs 8,600 people in more than 80 countries and generated revenue of EUR 874 million in 2009. Cegedim SA is listed in Paris (EURONEXT: CGM). To learn more, please visit: www.cegedim.com 

Click here to see all recent news from this company

SCOTTSDALE, AZ–(Marketwire – December 7, 2010) – miCARD and Gold Wing Road Riders Association, the world’s largest social organization for owners and riders of Honda Gold Wing/Valkyrie motorcycles have partnered to provide GWRRA with a co-branded, medical information card that prepares association member/riders for an unanticipated medical emergency.

“One of the highest priorities at GWRRA is to ensure the health and safety of our 74,000+ members,” said Ed Price, Marketing Director at GWRRA. “We are pleased to join forces with miCARD to ensure our association riders are prepared for any kind of a medical event. No matter where our members go, we know that the lifesaving medical information on miCARD will be with them. I personally carry miCARD in my wallet all the time, as I travel extensively.”

Motorcycle Fatalities on the Rise
The National Highway Transportation Safety Administration projects more than 100,000 motorcycle injuries will occur this year alone. Even with the advent of statewide motorcycle safety campaigns to help automobile drivers become more aware of motorcyclists, fatalities continue to rise. Carrying medical information ensures that emergency personnel have the critical information they need to make lifesaving decisions should an accident occur.

miCARD is the only medical information card and online Personal Health Record(PHR) designed by an emergency physician. In less than one minute, miCARD gives medical personnel in the field a readable summary of a member’s vital medical information. This includes: current medical conditions, critical medications, emergency contacts, allergies and more. miCARD’s wallet card is further supported by an online PHR which stores additional member information such as: advance directives, physician contacts, EKG’s, lab results, and current medications. All personal medical information is stored securely online and viewable at the miCARD website 24/7 by treating medical providers worldwide.

“Critical decisions about your health are made in the first few minutes of your emergency care,” said Dr. James Kelley, a practicing ER physician and co-founder of miCARD. “If you are unconscious or incapacitated, medical personnel have no knowledge of your existing medical conditions, critical medications or other important details which could impact your care and save your life.”

miCARD is a low cost solution to the problem of emergency preparedness and care and can be created securely online in minutes. To ensure the health and safety of your association members or to enquire about co-branding opportunities with miCARD please visit www.micard.com/partners or contact us directly at (866)596.2956.

About miCARD
Headquartered in Scottsdale, AZ, miCARD is a physician designed, medical information card and online personal health record designed to optimize emergency medical care. miCARD’s proprietary solution improves the flow of critical care information and ensures medical personnel have immediate and secure access to a user’s vital medical information, 24/7 worldwide. miCARD is registered with the USPTO under patent & trademark protection. For more information about miCARD please visit www.micard.com or contact us at (866)596.2956.

About Gold Wing Road Riders Association
 Founded in 1977, The Gold Wing Road Riders Association (GWRRA) is the world’s largest single-marque social organization for owners and riders of Honda Gold Wing/Valkyrie motorcycles. Dedicated to our motto, Friends for Fun, Safety and Knowledge, GWRRA members enjoy the freedom of belonging to a not-for-profit, non-religious and non-political organization with more than 800 active chapters, serving nearly 80,000 U.S., Canadian and international members in 53 foreign countries.

PORT WASHINGTON, NY–(Marketwire – December 7, 2010) – iiBIG returns to America’s Healthcare Silicon Valley to present the industry-leading Investment and M&A Opportunities in Healthcare, January 25-26, 2011, at the Nashville Convention Center in Nashville, Tennessee. In 2011, experts are predicting an increase in middle-market M&A deal flow in all sectors — however, healthcare will continue to lead all others. Now that financing is becoming easier to find, pent up demand for deals in the middle-markets, and especially in this sector, are expected to increase dramatically. At this conference, attendees will hear from and network with experts and insiders on the status of deal-making in the healthcare sector and how and where deals are getting done.

Executive Speaking Faculty Includes: Alvarez & Marsal; Bass, Berry & Sims PLC; Belmont Village Senior Living; Benesch, Friedlander, Coplan & Aronoff LLP; Bertram Capital Management LLC; Capella Health; Coker Capital Advisors; CredenceHealth; Cressey & Company LP; Diatherix Laboratories, Inc.; DOHI; Epsilon Securities, LLC; EpsteinBeckerGreen; GTCR Golder Rauner, LLC; Healthcare Finance Group, LLC; Healthcare Productivity Automation; IASIS Healthcare Corporation; Iora Health; MedSolutions; Nashville Health Care Council (NHCC); Oak Hill Capital Partners; Penn Medicine; PricewaterhouseCoopers; Raymond James & Associates; Regence Group (Blue Cross/Blue Shield Oregon and Utah); RehabCare Group, Inc.; Renal Advantage, Inc.; Riordan, Lewis & Haden Equity Partners; Sonenshine Partners; SunTrust Robinson Humphrey; Tenet Healthcare; and Vanguard Health Systems.

Conference Sponsors include: Bass, Berry & Sims PLC; EpsteinBeckerGreen (EBG); PricewaterhouseCoopers; SunTrust Robinson Humphrey; Alvarez & Marsal; Benesch; Healthcare Finance Group (HFG); Raymond James & Associates, Inc.; Coker Capital Advisors; Riordan, Lewis & Haden Equity Partners; Sonenshine Partners; and Whyte Hirschboeck Dudek S.C.

Register by December 31, 2010 and Save $200! Healthcare Providers: Register at $595
For more conference information and/or to register: http://www.iibig.com/F1101.

About iiBIG
iiBIG (International Institute for Business Information & Growth) is an unbiased, independent company dedicated to organizing business-to-business conferences and seminars for senior-level business executives. We provide learning and networking settings for some of the business community’s BIGgest thinkers — those who occupy the highest levels in their companies and organizations. Our events focus on the most pressing and timely issues facing decision-makers in today’s global economy. For more information, visit: http://www.iibig.com. 

PORT WASHINGTON, NY–(Marketwire – December 7, 2010) – iiBIG’s Pharma & Biotech Licensing & Partnering — scheduled for March 3-4, 2011 at the Doubletree Hotel San Diego Downtown in San Diego, CA — is designed to bring together EVPs, SVPs, Chief Business Officers, COOs and other Senior Management from Pharmaceutical and Biotech companies involved in licensing, business development and strategic alliances and partnerships. This educational and networking forum will provide insight and guidance to pharmaceutical licensing, business development and deal making executives from across the world — covering issues that will help pharmaceutical companies both large and small to structure the best deals, carefully monitor risks and, perhaps, find their next partner. Executives from across the country will gather together to exchange ideas and information. 

Key issues to be addressed include:

• What are the best practice strategies in developing an effective win-win licensing deal?
• Early versus Late Stage Partnering Opportunities
• Role of Corporate Investors in Today’s Deals
• The Evolving Business Model of Building a Biotech
• What Uncertain Financial Markets Mean for Deal-Making
• Maximizing Your Company Value Through Non-Traditional Alliances

Hear from representatives of large, medium, and small pharmaceutical as well as biotechnology companies as they share their insights on the evolving state of the industry. Some key faculty speakers include:

• Michael Shih, Senior Director, Business Development, Eisai Inc.

• Dr. Robert Baughman, PharmD PhD, Vice President Experimental Pharmacology, MannKind Corporation

• Linda A. Egger, PhD, CLP™, Senior Director, Scientific Liaison External Scientific Affairs – Diabetes and Obesity Licensing, Merck & Co.

• Dr. Sameeh M. Salama, Senior Director, Business Development, NAEJA Pharmaceutical Inc.

• Christoph Pittius, Ph. D., Executive Director, Business Development & Licensing, Novartis Oncology

• Daisy Rivera-Muzzio, Senior Director EP Product Licensing, Portfolio Development, Pfizer

• Allen Downs, Senior Executive Director, Licensing & Business Development, Purdue Pharma

• Michael D. Step, Senior VP, Corporate Development, Santarus, Inc.

• Gwen Melincoff, Senior Vice President of Business Development, Shire Pharmaceuticals

For complete information about this event visit: http://www.iibig.com/P1101.

About iiBIG
iiBIG (International Institute for Business Information & Growth) is an unbiased, independent company dedicated to organizing business-to-business conferences and seminars for senior-level business executives. For more information, visit: http://www.iibig.com. 

SAN DIEGO, CA–(Marketwire – December 7, 2010) – Adamis Pharmaceuticals Corporation (OTCBB: ADMP) announced the successful completion of a Phase 3 contraceptive trial of the company’s contraceptive gel product candidate named Savvy® (C31G). The study met its primary endpoint and was conducted by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH), in the Contraceptive Clinical Trials Network at 14 sites in the United States. The results of the NICHD study are published in Obstetrics and Gynecology, v.116, pages 1265-1273, in December, 2010.

The Phase 3 trial was a randomized, double-masked, controlled comparator study to assess whether a gel containing the spermicide, C31G, was non-inferior to Conceptrol®, a commercially available product containing nonoxynol-9 (N-9). The clinical investigators found that C31G was not inferior in contraceptive efficacy to the comparator drug Conceptrol®. Thus, the study met its primary objective. Moreover, the gel was well-tolerated and had a high degree of acceptability in women who completed the study. No drug-related serious adverse events were observed with C31G. Drug-related side effects of C31G were generally mild and did not lead to discontinuation.

Currently, all spermicides commercially available in the U.S. contain the active ingredient N-9 in a carrier such as a gel, film, cream, foam, suppository, or tablet. N-9 has been reported in some studies to cause irritant and allergic reactions in some users. Although the Conceptrol® product was effective and well-tolerated in the NICHD comparative trial, there were a significantly lower number of drug-related events with the C31G gel and fewer women discontinued the study due to drug-related side effects. In an interview with Reuters Health, lead researcher Dr. Anne E. Burke of The John’s Hopkins School of Medicine stated, “There are concerns with nonoxynol-9, such as vaginal side effects and genital irritation for some users. It seems that C31G might offer improvements in those regards.” C31G does not contain nonoxynol-9 and, if commercialized, may offer a welcome alternative for women who seek a non-hormonal method of contraception. 

C31G previously was the subject of two Phase 3 clinical trials conducted in Africa, supported by Family Health International and the United States Agency for International Development, to determine whether C31G was safe and effective for reducing women’s risk of acquiring HIV infection. The external independent Data Monitoring Committee reviewing those trials concluded in 2005 and 2006 that, while there were no safety concerns based on the results of the studies to date, continuing the trials would not allow the effect of C31G on HIV acquisition to be determined because of a lower than expected rate of HIV seroconversion in the trials. The committee determined that continuation of the trials was not warranted due to a lack of statistical significance between C31G gel and the vehicle control in the interim data. Accordingly, the trials were discontinued.

Adamis estimates that the market for a product with the characteristics of C31G to be in the $500 million range. Dr. Dennis J. Carlo, President and CEO, stated, that “Since the product does not fit in the core business of the company, Adamis is currently evaluating various out-licensing opportunities. We are currently in discussions with multiple organizations that have a focus or business unit in the area of contraception.”

About Adamis Pharmaceuticals

Adamis Pharmaceuticals has three wholly-owned subsidiaries: Cellegy Holdings, Inc.; Adamis Corporation; and Biosyn, Inc. Adamis Corporation has two wholly-owned subsidiaries, Adamis Laboratories and Adamis Viral Therapies. Adamis Labs has niche prescription products in the allergy and respiratory therapeutic area and intends to launch additional products in this area. Adamis Viral Therapies is focused on the development of patented, proprietary technologies for the potential treatment of human prostate cancer.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future results of operations or future financial performance, including, but not limited to the following statements: the company’s ability to successfully develop and market C31G assuming it is approved for marketing by the FDA and other regulatory authorities; regulatory issues or delays with the FDA; and the intellectual property protection that may be afforded by any patents or patent applications relating to C31G. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause Adamis’ actual results to be materially different from these forward-looking statements. These risks and uncertainties include, but are not limited to: whether C31G will be approved for marketing by the FDA and other regulatory authorities; whether the company will be able to obtain required funding to pursue activities relating to C31G; whether C31G is a commercially viable product and can be commercialized, manufactured, and marketed in a cost-effective manner; the extent of consumer demand for any such product; and whether any third party will be interested in entering into agreements relating to development and marketing of C31G. It is uncertain whether C31G will ever be commercialized or whether the company will ever realize revenues therefrom. Certain of these risks, uncertainties, and other factors, as well as other risks and uncertainties relating to the company’s business are described in greater detail in Adamis’ filings from time to time with the SEC, all of which are available free of charge on the SEC’s web site at http://www.sec.gov. Adamis expressly disclaims any intent to update any forward-looking statements.

NEW YORK, NY and JERUSALEM–(Marketwire – December 7, 2010) – The International Center for Autism Research and Education (ICare4autism), a New York-based charity, announced plans to create the world’s first Global Autism Center on Mt. Scopus in Israel, dedicated to catalyzing breakthrough innovation in autism research and treatment. In a ceremony at Jerusalem‘s City Hall hosted by Mayor Nir Barkat, ICare4autism’s President Joshua Weinstein signed an agreement paving the way for ICare4autism to acquire the campus of Bezalel Academy of Art in 2013, and convert it into a center, housing:

• State-of-the-art autism research facilities to serve as a platform for global collaboration.

• The world’s first university-level school of autism studies, to raise therapeutic standards worldwide.

• A model school, applying the latest research, technology and design to the needs of students across the Autistic Spectrum.

• A foundation to support transformative global collaborations in autism education and treatment.

Joshua Weinstein said, “To tackle the global autism epidemic, we need a community of researchers, educators and advocates that reaches across borders. Our new Center will give us the ability to convene and empower that community.”

Said Dr. Eric Hollander, Chairman of ICare4autism’s Scientific Advisory Council, “The Center will drive the research needed to discover the etiology of autism, ultimately leading to better methods of detection and treatment.”

Said Mayor Barkat, “We welcome ICare4autism’s plan to create a Global Autism Center on Mt. Scopus, and we look forward to the breakthroughs in research that will emanate from its campus to benefit the entire world.”

About Joshua Weinstein, MBA and MA Ed
Mr. Weinstein is the Founder of ICare4autism, which encompasses Shema Kolainu – Hear our Voices School and Center for Children with Autism in New York City, and Tishma – ABA School and Center for Children with Autism in Jerusalem, Israel.

About Dr. Eric Hollander, MD
Dr. Hollander, Chairman of the Advisory Council of ICare4autism, is a renowned psychiatrist on the faculty of Montefiore Medical Center University Hospital of Albert Einstein College of Medicine, former Chair of Psychiatry at the Mt. Sinai School of Medicine and Director of the Seaver and Greater New York Autism Center of Excellence.

id=”nav_links”>

TUSTIN, CA–(Marketwire – December 7, 2010) –   Radient Pharmaceuticals Corporation (RPC) (NYSE Amex: RPC) in partnership with Jaiva Technologies, today announced the formation of NuVax Therapeutics, Inc. (“NuVax”) — a wholly owned subsidiary of Radient Pharmaceuticals. The formation of NuVax Therapeutics is a strategic move on the part of RPC to enhance the Company’s Q2 2010 collaboration agreement with U.S.-based Jaiva Technologies — a biotechnology company focused on the research and development, distribution, marketing and sales of promising third?party healthcare technology products. 

NuVax, a clinical stage pharmaceutical company, aims to develop novel immune-gene therapeutics that have the potential to significantly impact and extend the quality of life for cancer patients. Through the newly formed NuVax Therapeutics, RPC and Jaiva Technologies will utilize RPC’s Combined Immunogene Therapy (“CIT”) cancer therapy to carry out human phase II clinical trials and develop products that will be first in-line therapies for largely unmet medical needs for cancer. The rights to RPC’s CIT technology are anticipated to be transferred to NuVax and 100% of future product development and commercialization, including the development and in-licensing of the up to five additional cancer-fighting technologies will be managed through NuVax under the leadership of Jaiva Technologies Founder, President and CEO Dr. Umesh Bhatia. Dr. Bhatia’s team will be responsible for engagement with clinical laboratories, hospitals and physicians in multiple international locations; conducting clinical trials for CIT technology; securing government approval for the use of CIT as a cancer therapy and vaccine throughout select markets; expansion and management of stage II clinical trials in multiple international locations including the U.S.; and full commercialization of CIT and all other in-licensed therapies in other select international markets. 

In 2001, RPC acquired CIT for approximately US$2 million in cash. The Company has since invested approximately US$1 million in additional capital for patent protection with a U.S. patent issued May 25, 2004. Developed by Dr. Lung-Ji Chang, CIT is a cancer therapy that works by simultaneously incorporating two genes directly into a patient’s tumor cells to enhance their immune system’s natural ability to destroy other cancer cells. CIT targets cancer cells for immunological attack while simultaneously stimulating a stronger immune response against the tumor cells. Dr. Chang currently serves as a consultant to RPC for the continued development of CIT and other gene therapies.

According to RPC Chairman and CEO Mr. Douglas MacLellan, “The formation of NuVax Therapeutics provides a unique platform to significantly accelerate and expand our planned collaboration with Jaiva Technologies, specifically as it relates to the commercialization of CIT, in-licensing new cancer therapies and conducting stage II human clinical trials to ultimately introduce these products to market. Simultaneously, it allows us to dedicate RPC resources to the continued worldwide commercialization of our Onko-Sure In Vitro Diagnostic cancer test. Together we anticipate success through both Companies to drive long-term growth and shareholder value.”

To support the growth and success of NuVax, RPC and Jaiva Technologies have established an internationally renowned executive and scientific team and board of directors that include RPC Chairman and CEO Mr. Douglas Maclellan, RPC COO and Chief Financial Officer Mr. Akio Ariura, Jaiva Technologies Founder, President and CEO Dr. Umesh Bhatia, RPC Board member Mr. Michael Boswell, Dr. Lung-Ji Chang, Professor of Molecular Genetics and Microbiology at the University of Florida Gainesville, and Dr. Afsaneh Motamed-Khorasani, Director of Oncology at RPC.

New to the team is Dr. Donald P. Francis — Dr. Francis worked for CDC from 1971 to 1992: smallpox (assigned to WHO) in India, Bangladesh, Sudan and the former Yugoslavia, cholera in Nigeria, Ebola in Sudan, Assistant Director, Hepatitis Division, Assistant Director, Virology Division. From 1981 he worked on HIV/AIDS: Coordinator of Laboratory Activities (Atlanta), Consultant to State of California (Berkeley) and San Francisco Mayor’s office. His AIDS efforts were chronicled in And the Band Played On, by Randy Shilts. In 1993 he joined Genentech where his HIV vaccine work began. In 1995, Dr. Francis co-founded a spin-off of Genentech called VaxGen where the world’s first efficacy trials were completed in the United States, Canada, Holland and Thailand. In 2004, Dr. Francis retired from VaxGen to establish a not-for-profit foundation, Global Solutions for Infectious Diseases, dedicated to developing vaccines for the less developed parts of the world. In 2009, the first successful HIV vaccine trial was reported. That trial used GSID’s vaccine combined in a “prime-boost format” with one from Sanofi. In addition to HIV, Dr. Francis works with international vaccine manufacturers on vaccines for dengue and influenza. He is a frequent consultant for WHO. Dr. Francis is anticipated to serve as an advisor and member of NuVax’s Board of Directors of NuVax.

After completing undergraduate studies at the University of California at Berkeley, Dr. Francis received his M.D. from Northwestern University and his Doctor of Science in Virology from Harvard. In addition, he completed his pediatric training at the University of Southern California Medical Center in Los Angeles and his infectious disease training at Harvard.

About Jaiva Technologies
Jaiva Technologies is a US?based biotechnology company founded by Dr. Umesh Bhatia that is focused on the research and development, distribution, marketing and sales of promising third?party healthcare technology products, including RPC’s CIT cancer therapy and vaccine.

About Radient Pharmaceuticals:
Headquartered in Tustin, California, Radient Pharmaceuticals is dedicated to saving lives and money for patients and global healthcare systems through the deployment of its FDA-cleared In Vitro Diagnostic Onko-Sure® Test Kits for colon-rectal cancer recurrence monitoring The company’s focus is on the discovery, development and commercialization of unique high-value diagnostic tests that help physicians answer important clinical questions related to early disease-state detection, treatment strategy and the monitoring of disease progression or recurrence. To learn more about our company, people and potentially life-saving cancer test, visit.

Forward-Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company’s operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

Click here to see all recent news from this company

ATLANTA, GA–(Marketwire – December 7, 2010) – The Southeastern Medical Device Association’s (SEMDA) 5^th annual conference will take place on March 29-30, 2011, adding a half day to the popular medical device event. Recognized as the premier gathering for the Southeast medical device industry, the conference balances presentations by medical device companies to investors with educational programs and networking opportunities.

Specifically designed to meet the needs of medical device industry professionals, the expanded format will allow additional time for educational and panel presentations, as well as one-on-one meetings.

Another addition for 2011 is a Gala Dinner, which will be held on March 29 at the Georgia Tech Hotel and Conference Center. The annual SpotLight Awards, which recognize individuals and companies that have made substantial contributions to the growth of the Southeastern medical device industry, will be presented during the dinner.

This year’s conference will be held at the Georgia Tech Global Learning Center, a midtown Atlanta conference facility that offers more room for presentations and meetings, complemented by state-of-the-art technology capabilities.

Other highlights will include:

• Keynote presentations from industry leaders
• Presentations from some of the region’s top existing and emerging medical device companies
• Workshops on a variety of topics including critical business issues affecting those within the industry
• Panel discussions by VCs and business development professionals, as well as a CEO Roundtable
• Numerous industry networking opportunities

For more information about the conference, sponsorship opportunities, presenting company application or registration, visit www.semdaconference.com.

About SEMDA
The Southeastern Medical Device Association (SEMDA) is a non-profit association that supports and promotes the medical device companies in the Southeast. Created in 2004, the association provides a unique resource and networking opportunity for medical device companies, entrepreneurs, inventors, physicians, and investors interested in accelerating the growth of the medical device industry in the Southeast. For more information, visit www.semda.net

Click here to see all recent news from this company

SCOTTSDALE, AZ–(Marketwire – December 7, 2010) – Stat Health Services Inc. and Scottsdale Healthcare announced today that they are offering Stat Health’s innovative STAT DOCTORS™ eHealth service as a supplemental health and wellness benefit for Scottsdale Healthcare’s employees and their covered dependents. 

Scottsdale Healthcare is the city of Scottsdale’s largest employer, operating three hospitals, a cancer center and several ambulatory care facilities with approximately 10,000 covered lives included in its employee medical plan. The agreement is Stat Health Services’ first contract with a major employer.

Like a virtual house call, STAT DOCTORS offers online on-demand care from a physician for many non-emergency minor illnesses or conditions. Effective today, Scottsdale Healthcare is launching the new employee benefit, just in time for the cold and flu season.

“With STAT DOCTORS our health plan participants will have the convenience of online access to board certified emergency physicians for care of common minor medical conditions, any time of the day or night. We believe this will be a popular benefit that our employees will take advantage of when they need care,” says Carol Henderson, senior vice president/chief talent officer for Scottsdale Healthcare.

55 percent of the 114 million visits to an emergency room are for non-emergencies¹. STAT DOCTORS leverages the Internet, advanced and proprietary technologies — including secure single sign-on, electronic health records (EHRs), ePrescribing and video conferencing — to bring patients a modern day virtual house call for treating minor medical emergencies.

By offering STAT DOCTORS, employers may benefit from increased employee satisfaction and retention, reduced employee absenteeism and decreased costs. Hospital employers such as Scottsdale Healthcare are also expected to benefit from their employees utilizing the STAT DOCTORS eHealth service for urgent care needs instead of hospital emergency rooms.

“In the past, patients had no choice but to either delay treatment or waste precious time and money waiting in emergency rooms or urgent care centers, exposed to seasonal viruses,” explains Alan C. Roga, M.D., Chairman and CEO of Stat Health. “Our STAT DOCTORS service solves this problem by using advanced technologies to provide convenient access to quality health care, 24 hours a day, 7 days a week.”

¹ “Addressing the Problem of Low Acuity Non-Emergent ER Visits,” Mercer Human Resources Consulting, January 2006.

About Scottsdale Healthcare
Scottsdale Healthcare is the community-based, nonprofit parent organization of the Scottsdale Healthcare Osborn Medical Center, Scottsdale Healthcare Shea Medical Center and Scottsdale Healthcare Thompson Peak Hospital, Virginia G. Piper Cancer Center at Scottsdale Healthcare, Scottsdale Healthcare Research Institute and Scottsdale Healthcare Foundation. A leader in medical innovation, talent and technology, Scottsdale Healthcare was founded in 1962 and is based in Scottsdale, Arizona. For more information, visit www.shc.org.

About Stat Health Services Inc.
Stat Health Services Inc. is an eHealth services company. Its STAT DOCTORS™ service provides members convenient and affordable online access to emergency medicine physicians for the diagnosis and treatment of urgent common minor medical conditions. STAT DOCTORS™ brings patients a modern day virtual house call. By providing such features as a secure single sign-on, a virtual waiting room, online medical consultations (eVisits), electronic health records (EHRs), and electronic prescribing (ePrescribing), STAT DOCTORS™ delivers a personalized, secure and superior health care experience. Stat Health’s network of emergency medicine physicians includes top board certified physicians who share a passion for delivering high quality health care, efficiently and effectively, by using the Internet and advanced technologies to treat today’s connected patients. Stat Health is headquartered in Scottsdale, Arizona. For more information, visit www.STATDOCTORS.com.

SAN DIEGO, CA–(Marketwire – December 7, 2010) – Mitchell International, Inc., a leading provider of information, workflow and performance management solutions to the Property & Casualty (P&C) claims and Collision Repair industries, today announced the successful close of its purchase of Ingenix’s P&C medical bill review (MBR) business. The purchase places Mitchell Workers’ Compensation Solutions (WCS) business and its SmartAdvisor™ medical bill review platform in a market leadership position, enabling the company to deliver to the insurance and managed care related industries advanced technology solutions with a proven track record of streamlining medical claims operations and improving cost containment.

“Since the intent to purchase the Ingenix MBR business was announced this October 20, Mitchell has experienced broad market acceptance and customer buy-in, the result of a carefully planned business and technology transition strategy that is being deployed within the context of Mitchell’s stable position and long-term experience in the P&C marketplace,” said Nina Smith-Garmon, senior vice president and general manager of the Mitchell Workers’ Compensation Solutions Division.

Smith-Garmon added, “The positive feedback we have received at the recent National Workers’ Compensation and Disability Conference® & Expo indicates that Ingenix P&C MBR customers anticipate a smooth, successful transition to Mitchell and the SmartAdvisor medical bill review technology platform. We will continue to enhance our solution for all our customers by adding to our already-extensive Preferred Provider Organization (PPO) networks and compliance expertise via strategic partnerships and acquisitions.”

Mitchell SmartAdvisor is a comprehensive bill review solution for workers’ compensation that leads the industry in its unique combination of performance software, client services, and best-in-class partnerships. Available through licensed or software-as-a service model, SmartAdvisor’s unique capabilities include customizable workflow modeling, Capstone® business decision rules engine, data analytics and reporting tools, Claims Examiner Portal for fast, secured, real-time access to bill data, and a proven technology platform that delivers on average 50-70% straight-through processing for improved efficiencies and lower costs. Visit www.mitchell.com/smartadvisor for more information or contact Mitchell Workers’ Compensation Solutions directly at 1-800-421-6705 to schedule a demo of the SmartAdvisor bill review system.

About Mitchell International, Inc.
Mitchell International (www.mitchell.com) is a leading provider of information and workflow solutions to the Property & Casualty claims and Automotive Collision Repair industries. The company’s comprehensive solution portfolio streamlines the entire auto physical damage, bodily injury and workers’ compensation claims processes. Mitchell enables millions of electronic transactions between more than 30,000 business partners each month to enhance partner productivity, profitability, and customer satisfaction.

About Mitchell Workers’ Compensation Solutions Division
Mitchell Workers’ Compensation Solutions (WCS), a division of Mitchell International, is a leading provider of workers’ compensation cost containment technologies and services. Insurance payers and other clients rely on Mitchell WCS’s best-of-breed medical bill review platform, the SmartAdvisor Software Suite, to improve their medical cost savings results. For more information, please visit www.mitchell.com/smartadvisor.

Click here to see all recent news from this company

SAN DIEGO, CA–(Marketwire – December 7, 2010) – Medistem Inc. (PINKSHEETS: MEDS) announced today the appointment of Dr. Vladimir Bogin as President and Chairman of the Board, Dr. Sergey Sablin as Vice President and Board Member, and Vladimir Zaharchook as Vice Chairman of the Board and Board Member. These changes were brought about as the result of a stock purchase agreement changing majority ownership of the company. 

“Dr. Sablin, who has a track record of excellence in drug discovery and development, is a founder of Selena Pharmaceuticals and a co-founder of Medivation, companies that advanced Dimebon, a Phase III technology that resulted in a deal with Pfizer with an over $200 million in the upfront payment. Dr. Bogin, a licensed physician with training from Brown and Yale, founded the contract research organization (CRO) Cromos Pharma, and has held Director-level positions with Big Pharma. Mr. Zaharchook is a successful businessperson and strategist. I am happy to entrust the future of our company in the hands of these experienced professionals,” said Dr. Neil Riordan, founder and former President and Chairman of Medistem, who resigned along with board member Dr. Roger Nocera as part of the acquisition. Dr. Riordan remains a shareholder and collaborator of Medistem. 

Medistem was founded in 2005 by Dr. Riordan as a developer, licensor, and licensee of adult stem cell therapeutics. To date technologies developed by Medistem have been used in more than 900 patients internationally. Currently Medistem, together with the Indiana company General Biotechnology, is nearing completion of additional experiments requested by FDA to allow for clinical trial initiation as part of its filed IND BB-13898 covering the use of Medistem’s “Endometrial Regenerative Cell” (ERC) product in patients at risk of amputation. 

ERC are a novel stem cell population isolated from menstrual blood that the company has demonstrated is capable of generating heart, brain, lung, liver, pancreatic, bone, muscle, blood vessel and cartilage tissue. Advantages of ERC include: a) lack of need for donor matching, allowing for “off the shelf” use; b) ability to be injected intravenously; and c) economical production in large scale.

“Dr. Riordan has pioneered the development of practical stem cell based products for treatments of debilitating conditions ranging from Multiple Sclerosis, to Duchenne Muscular Dystrophy, to Heart Failure. The intellectual property portfolio for these products, which are the basis of Medistem’s US-based developmental efforts, provide a deep pipeline of therapeutic candidates,” said Dr. Bogin.

“In contrast to companies who perform research for the sake of research, Medistem’s technologies are actually benefitting patients today, unfortunately only outside of the US. I was attracted to Medistem’s desire to make these treatments available to patients through the tried and tested FDA regulatory route,” said Mr. Zaharchook.

“The fact that Medistem’s ERC cells can be shipped to any facility in the US and administered without need for complex cell processing or injection procedures makes this stem cell product very attractive from a commercialization perspective,” said Dr. Sablin.

About Medistem Inc.
Medistem Inc. is a biotechnology company developing technologies related to adult stem cell extraction, manipulation, and use for treating inflammatory and degenerative diseases. The company’s lead product, the endometrial regenerative cell (ERC), is a “universal donor” stem cell being developed for critical limb ischemia. A publication describing the support for use of ERC for this condition may be found at http://www.translational-medicine.com/content/pdf/1479-5876-6-45.pdf. 

Cautionary Statement

This press release does not constitute an offer to sell or a solicitation of an offer to buy any of our securities. This press release may contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking information. Factors which may cause actual results to differ from our forward-looking statements are discussed in our Form 10-K for the year ended December 31, 2007 as filed with the Securities and Exchange Commission.

id=”nav_links”>

SOMERSET, NJ–(Marketwire – December 6, 2010) – TeamStaff, Inc. (NASDAQ: TSTF), a leading logistics and healthcare services provider to the Federal Government and Department of Defense announced today that its President and Chief Executive Officer, Mr. Zach Parker, will deliver a presentation to investors at the Third Annual LD MICRO Conference on Thursday, December 9, 2010 at 3:00pm PST. The conference is being held at the Luxe Sunset Boulevard Hotel in Los Angeles, California. A copy of the presentation will be made available in the Investor Relations section of the TeamStaff website (http://teamstaff.com/investor-relations) and also furnished as an exhibit to a Current Report on Form 8-K to be filed by the Company with the SEC.

“I’m pleased to present the TeamStaff story at this year’s LD MICRO investor conference as we believe we have laid the proper foundation to facilitate growth especially into adjacent markets with new customers, like the DoD. I am thankful to participate in this investor conference and I am looking forward to meeting with attendees who specifically have an interest in microcap companies,” said Zach Parker, Chief Executive Officer of TeamStaff.

“We are very pleased to have TeamStaff present at our third annual event,” said Chris Lahiji, President of LD MICRO. “I take pride in having an event that showcases companies of all sizes, in all industries. TeamStaff is a great addition to our roster this year.”

For more information on the conference or to register for the event, please visit http://www.ldmicro.com or call (408) 457-1042.

About TeamStaff, Inc.

TeamStaff serves clients and their employees throughout the United States as a full-service provider of logistics and healthcare support services. TeamStaff specializes in providing high quality healthcare, logistics, and technical services to Federal agencies and the Department of Defense. For more information, visit the TeamStaff corporate web site at www.teamstaff.com or the TeamStaff Government Solutions web site at www.teamstaffgs.com.

This press release contains “forward-looking statements” as defined by the federal securities laws and involve numerous risks and uncertainties. TeamStaff’s actual results could differ materially from those described in such forward-looking statements as a result of such risks and uncertainties. For a discussion of such risks and uncertainties, see “Risk Factors” in the Company’s periodic reports filed with the U.S. Securities Exchange Commission. The information in this release should be considered accurate only as of the date of the release. 

DEARBORN, MI–(Marketwire – December 6, 2010) – This year, more than 170,000 Michigan residents receive home-delivered health care from home health care providers, who make over 5 million home visits each year.

Many patients and their families prefer that their loved ones recuperate and/or receive rehab services for surgery, an injury or an acute illness in the comfort and familiar surroundings of their own homes. Trained clinicians, nurses, and therapists are able to provide the same level of attentive, compassionate and personalized in-home care as can be found outside.

Choosing a provider can often be a daunting and frustrating task. To aid the public, Dearborn-based Metro Home Health Care, a leading home health care provider in Michigan, is offering at no cost a Home Health Care Guide that provides basic information for people seeking a home health care agency.

The free booklet may be downloaded from the Metro Home Health Care website, www.metrohomehealthcare.com.

“We think the booklet offers specific things to look for in selecting a home health care agency, and what questions to ask before you make a decision,” said Dr. Agustin V. Arbulu, CEO of Metro Home Health Care. “Our mission has always been to provide best care available to the sick, the elderly or those recovering from surgery in their homes.”

Today’s home care professionals, volunteers, and modern medicine make it possible for people to stay in their homes longer and enjoy an improved quality of life.

Home health care has grown far beyond basic or simple professional nursing and home care aide services. Modern home care agencies like Metro Home Health Care offer a comprehensive scope of services including skilled nursing, physical, occupational, speech therapies, medical social work services, specialty wound care nursing, dietary education, and personal care.

“Metro Home Health Care always has the goal of independence in mind when caring for our neighbors,” said Arbulu.

Home care services are paid for by public and private sources, or directly by patients and their families. Medicare and state-run Medicaid are significant payers and often pay 100 percent of home health services for patients who qualify for such services. Third-party payers include commercial insurance, managed care organizations, and workers’ compensation. Despite deep cuts in government funding, home care continues to be the preferred means of receiving quality health care services for millions of Americans.

With offices in five cities covering 10 counties, Metro Home Health Care provides comprehensive in-home and supportive services for the entire Michigan lower peninsula to acute and chronically ill patients and their families. For more information, please call 313-336-6303 or 800-462-5632, or visit www.metrohomehealthcare.com.

Click here to see all recent news from this company

CHICAGO, IL–(Marketwire – December 6, 2010) – Physicians in three out of four medical groups of Resurrection Health Care Preferred (RHCP) have earned 11 blue stars — a perfect score — in the 2010 Blue Star Report. The report is a ranking of HMO contracting medical group physicians that have documented high levels of performance in providing patient care from Blue Cross Blue Shield of Illinois (BCBSIL). The Resurrection Health Care Preferred groups earning 11 stars are: Saint Joseph Health Preferred, Saint Mary and Elizabeth Health Preferred and Saint Francis Health Preferred. One group, Resurrection Health Preferred, earned 9 out of 11 stars.

Of the 96 Chicagoland medical groups surveyed, only eight received all 11 blue stars, three of which were part of Resurrection Health Care Preferred. All of the Resurrection Health Care Preferred medical groups received the Blue Ribbon designation — awarded for high patient satisfaction. All of the patients who had RHCP doctors rated their overall satisfaction with their doctor at above 91%.

The medical group’s doctors earn a blue star every time they meet or exceed the target care goal in each of the eleven reporting categories, including asthma care, breast cancer screenings, cardiovascular disease, childhood immunizations, controlling high blood pressure, colorectal screenings, diabetes care, influenza vaccinations, mental health follow-up, cervical cancer screenings and patient safety.

For more information about making Resurrection Health Care Preferred your choice for all your health care needs, call 773-572-8300 and ask for Member Services or visit us at http://www.reshealth.org/findadoctor/why_rhcp.cfm

Resurrection Health Care is the largest Catholic health care system in Chicago with over 100 sites of care. http://www.reshealth.org/

Follow us on Twitter: http://twitter.com/RHC_Outpatient
Visit our YouTube channel: http://www.youtube.com/user/ResurrectionHealth
Join us on Facebook: http://www.facebook.com/pages/Resurrection-Health Care/73879323438?ref=ts  

Click here to see all recent news from this company

THOUSAND OAKS, CA and POTTSTOWN, PA–(Marketwire – December 6, 2010) –  Amgen Inc. (NASDAQ: AMGN) http://www.amgen.com awarded IT&E International http://www.iteinternational.com/ top honors as Veteran-Owned Small Business Contract Staff Supplier in its Supplier Diversity Program.

According to Audrey Porter, IT&E International Vice President, “A special flag-raising ceremony at Amgen’s Thousand Oaks, California headquarters hosted by the Supplier Diversity program was attended by Rocky Chavez, California Secretary of Veteran Affairs, Debbie Gregory Co-Chair of the Veteran and Military Business Owners Association, Ryan Funderburg of IT& E International, and senior Amgen leadership.

“We are extremely grateful to Amgen for this recognition,” continued Ms. Porter, “and appreciate the opportunities to help the company make significant strides in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses,” she said.

About Amgen’s Supplier Diversity Program

Amgen has established a Supplier Diversity Program to ensure that small businesses are not excluded from participating in the supply of goods and/or services required by Amgen. Amgen is committed to identifying and awarding contracts to small, disadvantaged, women-owned businesses consistent with Amgen’s requirements. Amgen strives to identify, develop, and utilize small, disadvantaged, veteran, disabled veteran, and women-owned business enterprises, as well as Historically Underutilized Business Zones (HUBZone), in our procurement program. Amgen’s intent is to support economic development efforts to the extent that jobs may be provided, entrepreneurship may be advanced, and useful goods and/or services may be procured at competitive prices.

About IT&E International

IT&E International offers global regulatory compliance and validation services throughout the product development lifecycle. Consulting services include regulatory planning, providing skilled personnel for development operations, data management to ensure FDA compliance, and validation of new pharmaceutical manufacturing facilities. IT&E International provides our qualified, technical employees to work at pharmaceutical, biotech and life sciences organizations site under client supervision in FDA regulated areas. The company is headquartered at 1610 Medical Drive, Suite 210Pottstown, PA 19464; tel: (610) 340-2012; fax: (610) 340-2007; www.iteinternational.com

TUSTIN, CA–(Marketwire – December 6, 2010) – In its 12 year history, cardiovascular, dermatology and metabolic CRO Integrium has developed and managed over 150 successful clinical trials for clients, consistently beating patient enrollment goals and reducing costs. Integrium provides a therapeutic focus based on deep experience in cardiovascular, dermatological and metabolic trials of all sizes in regions around the world. On the basis of this experience the company offers a full range of services that combine innovative cutting-edge science and technology with practical clinical operations and involve working hands-on with clients, investigators and vendors to deliver high quality service with a sense of immediacy.

Integrium’s smaller size enables it to be far more nimble, and develop a personal rapport and trust with its clients in a way that “mega CROs” simply cannot. 2011 will mark the beginning of Integrium’s 13th year in this highly competitive market, a year the company will usher in with a large cadre of return clients and a team of passionate employees whose dedication is underscored by some of the lowest employee turnover in the business. Its exceptional performance recently caught the attention of the prestigious British pharmaceutical industry journal Scrip Clinical Research, which included Integrium in a cover story on specialty CROs, citing the launch of its dermatological practice as an example of a niche strategy worth watching.

Key Integrium Milestones/Metrics

• 12-year anniversary
  • Founded in 1998 by clinical research thought leaders Dr. David H.G. Smith, MD and Dr. Joel M. Neutel, MD. Dr. Smith and Dr. Neutel continue to lead the company today.
  • Established formal alliances with regional partner CROs in Europe, Australia and India, with numerous additional Integrium locations in North America and South Africa
• 150 successful clinical trials for clients
  • Tightened patient enrollment timelines dramatically and reduced study spend for clients such as Graceway Pharmaceuticals and Resverlogix
  • Consistently differentiated itself by demonstrating a deep understanding of the complexities and nuances of clinical research in its three core focus therapeutic areas: cardiovascular disease, metabolic disease and dermatology
  • Underscoring its success in these trials, 63% of Integrium’s business is with clients for whom it has managed clinical trials before
• Added Dermatology Clinical Research Group in June 2010
  • Helps Integrium clients design scientifically rigorous yet feasible dermatology studies, leveraging its relationships with reliable, high-quality investigators to help identify and recruit study patients, and effectively manage their studies from start to finish
  • Led by noted dermatology drug development expert Dr. Mary Spellman
• In a business where qualified, motivated professionals are critical to success and turnover is high, Integrium has some of the lowest turnover in the industry, with over 90% of the team remaining intact

Commentary
Dr. David Smith, MD, Founding Partner and Chief Medical Officer, Integrium: “Patient recruitment, enrollment and retention continue to represent a critical bottleneck in clinical research and drug development. We are proud of the results we’ve achieved with clients like Graceway and Resverlogix to ensure that they have the patient subjects they need to get the highest-quality data to run better, safer trials.”

Eileen McAuley, RN, BS, MPA, Chief Operating Officer, Integrium: “We take our mission statement seriously, focusing on integrity as a core value. This translates into our dedication to personalized service from the start of a client’s clinical trial to its completion, rigorous scientific protocols, and unyieldingly high research standards. We are not striving to be the biggest CRO — just the best.”

Dr. Sharon Levy, MD, Senior Vice President of Product Development, Graceway Pharmaceuticals: “Integrium’s keen understanding of our specific therapy areas allows us to stay focused on our primary trial objectives. For a multi-center Phase 2 trial they helped us enroll and randomize many more patients than we thought possible — and did so with a very small drop-out rate and 19 weeks ahead of schedule.”

Dr. Allan Gordon, MD, Ph.D, Senior Vice President, Clinical Development, Resverlogix: “Integrium understands that trial efficiencies come from the ground up. The services team understood that we required a ‘true’ partnership and that success would come from understanding our needs and the complexities inherent in running a 40-site study — and their results exceeded our expectations. That they reduced our cycle so dramatically — by nearly six months — allowed us to come in under budget and see the site results we hoped for.”

Resources

• Press release announcing successful trials with Graceway Pharmaceuticals and Resverlogix
• Press release announcing launch of Dermatology Clinical Research Group
• Overview of Integrium’s expertise as a cardiovascular, dermatology and metabolic CRO
• Follow Integrium on LinkedIn

About Integrium, LLC
Integrium is a therapeutically-focused, full-service contract research organization that specializes in dermatology, cardiovascular and metabolic clinical research. It has a strong reputation for delivering high-quality management of global clinical development programs and service to its clients. Combining the Integrium Clinical Excellence (ICE) study start-up and management methodology, and therapeutic expertise leads sponsors to more confident, better-informed drug and device development decisions. For more information please visit http://www.integrium.com.

CAMBRIDGE, MA–(Marketwire – December 6, 2010) – InterSystems Corporation, the global leader in software for connected healthcare, today announced that the University of Colorado Hospital (UCH) has chosen the InterSystems Ensemble® rapid integration and development platform for enterprise-wide integration.

InterSystems specializes in advanced integration, database, and business intelligence technologies for breakthrough applications. UCH is recognized as one of the leading hospitals in the nation and is consistently recognized among the top hospitals in the country by U.S. News & World Report. Most recently, UCH has been cited as one of the top 10 academic medical centers in the country based on quality, patient safety and patient satisfaction, according to the 2010 Quality and Accountability Performance Scorecard, released by the University HealthSystems Consortium.

Strategy Change Drives Integration Platform Search

“For years, our strategy had been tied to the best-of-breed concept, which resulted in a very decentralized system with more than 150 unique interfaces,” said Peggy Dalious, UCH Applications Director. “Then, we made the decision to move to the InterSystems CACHÉ-based Epic Systems electronic health record application, which required major alterations to our IT plans.”

“We recognized that the integration engine represented a key piece of our infrastructure before we entered what is going to be a mass application overhaul,” Dalious continued.

The change in strategy came at a time when UCH was increasingly uneasy about its legacy integration platform, noted Dalious. The acquisition of the product’s company by another vendor, followed by the acquisition by yet another vendor, added a layer of complexity to working with the product.

“Our interface engineers had heard about Ensemble and thought it might be the right integration option for UCH,” Dalious said. After extensive research and interaction with multiple Ensemble customers, “we had a strong, sensible case for moving to Ensemble.”

The foundation for the Ensemble transition was developed based on a proof-of-concept project. UCH specified two difficult interfaces that would have to be built via Ensemble for the POC. InterSystems reviewed the interfaces onsite and defined the requirements, with UCH software specialists building the interfaces under the guidance of the InterSystems team.

Moving Forward on Solid Foundation

Following the success of the proof-of-concept, UHC has gone live with approximately 35 Ensemble-based interfaces with a core group of applications including human resources and ERP systems that will not be replaced by the Epic implementation. Plans are to go live in 1Q11 with the Epic ambulatory clinics application with Epic outpatient and inpatient modules and a total of about 85 interfaces rolling out through 3Q11.

“We’re already beginning to see how we can use other Ensemble capabilities once the interface migration from the legacy platform is complete,” Dalious said. “We know that features such as workflow management and business activity monitoring are available in Ensemble and we plan to take advantage of those facilities in the future.”

“Ensemble delivers the advanced technology required for strategic breakthroughs like the one now being realized by UCH,” said Paul Grabscheid, InterSystems Vice President of Strategic Planning. “As the healthcare industry continues to rapidly evolve, we are committed to partnering with our customers who leverage our software to optimize care delivery.”

About InterSystems

InterSystems Corporation is a global software technology leader with headquarters in Cambridge, Massachusetts, and offices in 23 countries. InterSystems provides advanced software technologies for breakthrough applications. InterSystems CACHÉ® is a high performance object database that makes applications faster and more scalable. InterSystems Ensemble® is a seamless platform for integration and the development of connectable applications. InterSystems HealthShare™ is a platform that enables the fastest creation of an Electronic Health Record for regional or national health information exchange. InterSystems DeepSee™ is software that makes it possible to embed real-time business intelligence capabilities in transactional applications.

InterSystems is the world’s #1 vendor of database and integration technologies for healthcare applications. InterSystems products are used by thousands of hospitals and labs worldwide, including all 14 hospitals on the Honor Roll of America’s Best Hospitals as rated by U.S. News and World Report. For more information, visit InterSystems.com.

About University of Colorado Hospital

University of Colorado Hospital is the Rocky Mountain region’s leading academic medical center, and has been recognized as one of the United States’ best hospitals, according to U.S. News & World Report. It is best known as an innovator in patient care and often as one of the first hospitals to bring new medicines to patients’ bedsides. Located at the Anschutz Medical Campus in Aurora, Colo., the hospital’s physicians are affiliated with the University of Colorado School of Medicine, part of the University of Colorado system. For additional information, go to www.uch.edu.

BALTIMORE, MD–(Marketwire – December 6, 2010) – eMarkets Group LLC, the distributor of HealFast® Therapy, disposable drug-free anti-inflammatory medical devices manufactured by BioElectronics Corporation (PINKSHEETS: BIEL), today announced the introduction of a new Quick Relief Loop. The Quick Relief Loop will be available at the breakthrough price of $15.00 for 100 hours of continuous pain relief therapy. 

The new product is on display this week at the annual convention of the American Association of Equine Practitioners in Baltimore.

“The award-winning BioElectronics team has made cost-reduction engineering improvements that enable the breakthrough new pricing,” said Mary K. Whelan, President of eMarkets Group. “BioElectronics technology was cited by the Wall Street Journal as one of the best innovations of 2009. Now the Quick Relief Loop pricing makes cost-effective, drug-free pain relief available to much larger markets.” 

Whelan explained that the new Quick Relief technology is available in the US only in the veterinary market initially. HealFast Therapy is currently in use in leading equine treatment centers and has been recommended by both equine and small animal veterinarians.

Mac Stein is a physical therapist who has used HealFast Therapy extensively. “I have had very good results using the patch on a variety of acute and chronic conditions. The new lower cost unit will be ideal for problems like strains and tendonitis as well as wounds and abscesses which respond rapidly to the continuous application of PEMF Therapy.” Mac Stein will be available to speak with veterinarians at the AAEP Conference Exhibit Hall, booth 704.

The Company said that earlier PEMF therapy delivery systems required cumbersome devices or repeated office visits. The HealFast Therapy Quick Relief patch joins the HealFast family of PEMF products that are available in a range of shapes and sizes for different veterinary uses and are priced from $89.95 for long lasting units with on/off switches to the new $15.00 unit for 100 hours of continuous treatment.

eMarkets Group, the global veterinary distributor of BioElectronics products, markets and sells the product through veterinarians and therapists and on its web site, http://www.healfasttherapy.com. HealFast Therapy is developed and manufactured by BioElectronics Corporation (PINKSHEETS: BIEL), which has extensive worldwide patents and patents pending.

For more information visit http://www.healfasttherapy.com or call 1-888 9 HEALFAST (1-888-943-2532) or 551-200-5586.

About HealFast Therapy
HealFast Therapy is a wearable patch with an embedded microchip that delivers continuous PEMF therapy for horses, cats and dogs. HealFast Therapy is a wearable, disposable patch with an embedded microchip that delivers continuous PEMF therapy for horses, dogs and cats. The patch is a state-of-the-art safe treatment option for relieving pain, edema and inflammation as well as enhancing repair of various types of wounds. HealFast Therapy is distributed by eMarkets Group, LLC, North Caldwell, NJ.

About BioElectronics Corporation
BioElectronics Corporation is the developer and manufacturer of advanced medical devices. Its products are ActiPatch® Therapy, for over-the-counter treatment of back pain and other musculoskeletal complaints, the Allay™ menstrual cycle pain therapy, and RecoveryRx for surgical procedures and wound care. The unique therapy delivery system, using patented technology, provides a cost-effective home care to reduce soft tissue pain and swelling. For more information, please see www.bielcorp.com.

Click here to see all recent news from this company

SAN DIEGO, CA and NEW YORK, NY–(Marketwire – December 6, 2010) – Mitchell International, Inc., a leading provider of information, workflow and performance management solutions to the Property & Casualty claims and Collision Repair industries and CoreChoice, the nation’s fastest growing specialty network devoted entirely to radiological services today announced the execution of a multi-year contract. Claims professionals, via Mitchell DecisionPoint^®, the leading medical bill management solution for 1^st and 3^rd party liability claims handlers, can now access the depth and breadth of the CoreChoice radiology network; which includes highly specialized services such as MRI (Open and Closed), Mammography, Sonogram, X-Ray, Nuclear Medicine services and CT, PET and Bone Scan services. This provides for an enhanced ability for insurers to ensure maximum value delivered to policyholders within their coverage limits via the benefits of pre-negotiated contract rates with CoreChoice facilities.

“CoreChoice is an established leader in the provision of a broad set of high quality radiological services,” said Dave Torrence, Senior Vice President and General Manager, Mitchell International. “Our relationship with CoreChoice is a natural and synergistic extension of the capabilities of both of our organizations to the benefit of our customers, who elect to implement CoreChoice, and — most importantly — to injured parties. We know and understand that specialized procedures, including radiological services are driving costs up nationally and we’re excited about extending our capabilities in offering CoreChoice.”

Mitchell is pleased to provide additional benefits for its customers through this new agreement with CoreChoice, including:

• The service and quality of care results they demand in their claims handling organizations via the ability to provide injured parties — including those who might not otherwise have convenient access to such an extensive range of top quality radiological services — the benefit of more than 6,000 CoreChoice imaging centers throughout the nation, including Washington D.C. and Puerto Rico;
• Maximum efficiency and productivity of claim handlers. DecisonPoint provides a “single source solution” enabling claims professionals to save time by reducing the use of a variety of disparate claims handling solutions as well as the high amounts of manual processing often required to access the benefits of specialty medical networks;
• Elimination of billing negotiations as medical billings from CoreChoice facilities are quickly paid via pre-established contractual rates; and
• A fully integrated and modern medical bill review technology solution that is compliant with standard HIPAA and ANSI X12 data transmission requirements.

Accessibility to CoreChoice networks via Mitchell’s state-of-the-art bill review offerings provides CoreChoice network members significant expansion opportunities. “There is exponential growth in the use of radiological procedures in healthcare,” said Steven F. Gass, Chief Executive Officer, CoreChoice. “CoreChoice is dedicated to providing injured parties the highest quality radiological services available and our Mitchell relationship offers us significant opportunities to expand our reach to assist injured parties to receive prompt, effective, proper and reasonably priced medical care.”

About Mitchell DecisionPoint

Mitchell DecisionPoint® is the leading medical bill management solution for 1^st and 3^rd party liability claims handlers reviewing more than 13 million medical bills each year representing more than $11 billion in medical provider billed charges. DecisionPoint is in use by more than 40 top US property casualty insurers including 8 of the 10 largest automobile insurers representing more than 60 percent of direct written premium in the personal auto lines market.

About Mitchell International, Inc.

Mitchell International (Mitchell) is a leading provider of information and workflow solutions to the Property & Casualty claims and Automotive Collision Repair industries. The company’s comprehensive solution portfolio streamlines the entire auto physical damage, bodily injury and workers’ compensation claims processes. Mitchell enables millions of electronic transactions between more than 30,000 business partners each month to enhance partner productivity, profitability, and customer satisfaction. For more information please visit www.mitchell.com

About CoreChoice

CoreChoice combines the talents and expertise of medical, technology, and insurance industry professionals to provide a new level of radiology network service. Our philosophy is to provide the largest radiology specialty network in the United States with fair and equitable pricing as well as a prompt pay mechanism for our participating network facilities. For more information please visit www.corechoice.net.

VANCOUVER, BC–(Marketwire – December 6, 2010) – Digital Payment Technologies (http://www.digitalpaytech.com) (DPT), a leading supplier of parking technology and solutions, today announced that the city of Houston, Texas, will roll out an additional 250 of the company’s LUKE pay stations, marking a significant expansion of an already successful deployment program. On December 8, DPT will host a webinar with Houston’s director of parking management, Liliana Rambo, CAPP, who will share insights gained from her experience planning and implementing a large-scale parking technology transition that has been favorably met by officials and the public in the fourth largest city in the U.S.

The 250 new LUKE pay stations will be configured similarly to those in the original deployment that began in 2006. They will connect to the city’s back-end parking management systems via Wi-Fi, will accept coins, bills and credit cards, and in the future will be able to accept payment by cellular phone. This brings the total number of DPT pay stations in Houston to 1,000, and marks yet another milestone in a tremendously successful program.

“DPT pay stations enable Houston’s parking management division to meet its objectives of delivering superior service to consumers and optimizing operational efficiency,” said Rambo. “In these difficult economic times, the operational efficiency and increased revenue made possible by these advanced parking systems have enabled the city to continue to fund many important municipal programs.”

Houston’s project was initiated to replace outdated single- and double-head parking meters, improve the parking experience for the public, reduce traffic congestion, increase parking turnover and improve the bottom line. By implementing a comprehensive rollout plan that included a variety of communications strategies with key stakeholders throughout the process, Houston’s Parking Management Division has secured some impressive results, including:

• 80 percent revenue increase without an increase in parking rates.
• 33 percent productivity improvement for meter operations staff.
• 1,000 more paid citations per month, equal to $58,000 in revenues, due to citations being upheld in adjudication. The new technology leaves less room to dispute tickets.

DPT’s December 8^th webinar will provide additional details and best practices from this $15.4 million advanced parking project that will be useful to municipal, county and state government departments, as well as private parking operators responsible for parking and enforcement. Free registration is available at: http://event.on24.com/r.htm?e=265402&s=1&k=8C1A49910D44B77405A4E608E0F0843D&partnerref=dpt1

“The City of Houston’s use of multi-space pay stations is a testament to the positive impact that smart parking initiatives can have on a city,” said Alan Menezes, vice president of product management and marketing with Digital Payment Technologies. “There is a great opportunity for cities that still rely upon single-head parking meters to institute a similar parking plan and reap the benefits. Our customizable pay stations, back-end services and support and seamless integration with leading industry partners put DPT in the unique position of offering a complete parking solution composed of best-in-class components. Furthermore, DPT has significant experience helping large and small municipalities ensure a smooth transition as they embrace multi-space parking.”

Houston/DPT Webinar Details:
Date: Wednesday, December 8, 2010
Time: 2:00 p.m. EST / 11:00 a.m. PST
Cost: Free
Register: http://event.on24.com/r.htm?e=265402&s=1&k=8C1A49910D44B77405A4E608E0F0843D&partnerref=dpt1 

About Digital Payment Technologies
Digital Payment Technologies (DPT) is an innovative leader in the design, manufacture, and distribution of electronic parking meters, management software, and online services for the parking industry. DPT products provide complete financial tracking, control, and reporting on parking revenue collected by cities, municipalities, universities, parking management companies, private operators, and national parks, from customer payment through to bank deposit. In 2007, DPT was named Emerging Company of the Year by the British Columbia Technology Industry Association, and has been included on multiple Deloitte Technology Fast 50 and Fast 500 lists as one of the fastest growing high technology companies in North America. For more information visit: http://www.digitalpaytech.com

Click here to see all recent news from this company

OTTAWA, ONTARIO–(Marketwire – 6 déc. 2010) – Alors que le Canada songe au renouvellement de son Accord sur les soins de santé en 2014, les principaux intervenants en santé publique sont optimistes quant à la mise sur pied d’un registre national d’immunisation, déclare Debra Lynkowski, présidente-directrice générale de l’Association canadienne de santé publique (ACSP).

« Notre réponse typiquement canadienne aux problèmes d’immunisation plus vastes a malheureusement entraîné des approches diverses au pays », affirme Debra Lynkowski. « Maintenant, alors qu’on approche du renouvellement de l’Accord sur les soins de santé, en 2014, le moment est venu de mettre sur pied un registre national d’immunisation harmonisé. »

Nous reconnaissons qu’une demande de financement supplémentaire auprès des gouvernements peut sembler invraisemblable dans le présent contexte fiscal, mais une stratégie nationale d’immunisation basée sur un registre national, soutenu par toutes les provinces et les territoires, assurerait une protection équitable des Canadiens contre les maladies évitables par la vaccination, et ce, peu importe leur lieu de résidence, leur âge ou leur statut socio-économique.

« Tous les Canadiens devraient avoir un accès égal à l’immunisation contre les maladies évitables par la vaccination. Le lieu de résidence ne devrait pas avoir d’incidence quant à l’accès aux programmes d’immunisation », soutient Debra Lynkowski.

Les améliorations découlant d’une stratégie nationale d’immunisation comprendraient une harmonisation des calendriers de vaccination pour les enfants partout au pays, un alignement de l’introduction des nouveaux vaccins et une égalité d’accès aux vaccins dans toutes les provinces et territoires. La collecte méthodique de données relatives à l’immunisation dans un registre national d’immunisation modernisera la façon dont les autorités transmettent les dossiers d’immunisation des patients et aidera à assurer des taux de couverture suffisamment élevés partout au pays afin de mieux protéger les Canadiens.

Debra Lynkowski souligne qu’une stratégie nationale promouvrait aussi de meilleures possibilités de recherche, la promotion de vaccins, ainsi qu’une meilleure éducation des fournisseurs de soins de santé et du public. À l’heure actuelle, le Canada n’a pas de calendrier harmonisé de vaccination systématique pancanadienne.

« En bref, il vaut mieux prévenir les maladies que d’avoir à les traiter », conclut Debra Lynkowski.

Ces recommandations sont le résultat d’un dialogue continu sans précédent que tiennent les dirigeants du gouvernement et les principaux intervenants de l’industrie et des secteurs de la santé publique et des soins de santé.

Fondée en 1910, l’Association canadienne de santé publique (ACSP) est le porte-parole de la santé publique au Canada. L’indépendance de l’ACSP, ses liens avec la communauté internationale et le fait qu’elle soit la seule organisation non gouvernementale canadienne à se consacrer exclusivement à la santé publique la placent en position idéale pour conseiller les décideurs à propos de la réforme du réseau de santé publique et pour orienter les initiatives visant à protéger la santé individuelle et collective au Canada et dans le monde. Grâce à son effectif diversifié représentant plus de 25 professions, son efficacité démontrée, son approche de collaboration et son envergure nationale, l’ACSP est le chef de file canadien en santé publique. 

Contexte

L’ACSP travaille activement avec les principaux intervenants de l’industrie pour créer un contexte favorable à une stratégie nationale d’immunisation qui protégerait les Canadiens contre les maladies évitables par la vaccination. Pour faciliter un dialogue continu, l’ACSP a organisé une table ronde en 2009 avec les principaux intervenants et a depuis participé à diverses activités d’échange d’information organisées par d’importants organismes nationaux. 

En outre, pour assurer une réponse dans les meilleurs délais à la pandémie H1N1 de l’année dernière, l’ACSP, en collaboration avec l’Agence de la santé publique du Canada, l’Association médicale canadienne, le Collège des médecins de famille du Canada et la Société nationale de spécialistes pour la médecine communautaire, a mis au point l’outil « GRIPPE PANDÉMIQUE H1N1 — Aide-mémoire à l’intention des cliniciens de première ligne ».

En réponse à l’importante demande de renseignements en plus des renseignements déjà offerts par le gouvernement du Canada, l’ACSP a fondé des centres d’échange d’information canadiens sur la grippe H1N1 comme autre source non gouvernementale de renseignements fiables pour les Canadiens.

En tant que secrétariat pour la Coalition canadienne pour la sensibilisation et la promotion de la vaccination, l’ACSP fait office de facilitateur et de coordonnateur d’activités de la Coalition pour réduire au minimum les chevauchements et s’assurer que les Canadiens reçoivent des messages cohérents concernant l’immunisation.

Un document d’information est disponible à l’adresse suivante : http://media3.marketwire.com/docs/cpha-fre.pdf

OTTAWA, ONTARIO–(Marketwire – Dec. 6, 2010) – As Canada looks to the renewal of its Health Accord in 2014, public health leaders are hopeful room can be found for the creation of a national immunization registry, says Debra Lynkowski, Chief Executive Officer, Canadian Public Health Association (CPHA).

“Unfortunately, our typically Canadian response to broader immunization issues has resulted in a patchwork of approaches across the country,” said Lynkowski. “Now, as we approach the renewal of the Health Accord in 2014, is the time for a harmonized, national immunization registry.”

While we recognize additional funding may seem an improbable request of governments in the current fiscal environment, a national immunization strategy that includes at its core a national registry, one supported by all provinces and territories, would ensure Canadians are equitably protected against vaccine-preventable illnesses, regardless of where they live, their age or their socio-economic status.

“All Canadians should have equal access to immunizations for vaccine-preventable diseases. Where you live should have no bearing on access to immunization programs,” said Lynkowski.

Improvements stemming from a national immunization strategy would include harmonization of childhood immunization schedules across the country, aligned introduction of new vaccines, and equal access to vaccines across all provinces and territories. The systematic collection of immunization data in a national immunization registry will modernize the way jurisdictions communicate patients’ immunization histories and help to ensure coverage rates are high enough throughout the country to best protect Canadians.

A national strategy would also promote better opportunities for research, vaccine promotion and improved education of health care providers and the general public, said Lynkowski. Currently, Canada lacks a harmonized cross-country routine immunization schedule.

“Simply put, it is better to prevent disease and illness than to have to treat it,” said Lynkowski.

These recommendations are a result of unprecedented and ongoing dialogue with government leaders, industry and public health and health care stakeholders.

Founded in 1910, the Canadian Public Health Association (CPHA) is the independent voice for public health in Canada with links to the international community. As the only Canadian non-governmental organization focused exclusively on public health, CPHA is uniquely positioned to advise decision-makers about public health system reform and to guide initiatives to help safeguard the personal and community health of Canadians and people around the world. With a diverse membership representing more than 25 professions, a track record of success, a collaborative approach and national reach, CPHA is Canada’s Public Health Leader.

Background

CPHA has been working actively with stakeholders to improve the environment for a national immunization strategy that would protect Canadians against vaccine preventable diseases. To facilitate an ongoing dialogue, CPHA organized a roundtable discussion in 2009 with stakeholders and has since participated in various information-sharing activities organized by leading national organizations.

In addition, to ensure timely response to last year’s H1N1 pandemic, the CPHA, in collaboration with the Public Health Agency of Canada, the Canadian Medical Association, College of Family Physicians of Canada and the National Specialty Society for Community Medicine developed “PANDEMIC H1N1: Fast facts for front-line clinicians.”

In response to a significant demand for information in addition to what was available from the Government of Canada, CPHA established the Canadian H1N1 Information Clearinghouse as an additional, non-governmental source of reliable information for Canadians.

As secretariat for the Canadian Coalition for Immunization Awareness and Promotion, CPHA facilitates and coordinates the activities of the Coalition to minimize duplication and ensure that Canadians receive consistent immunization messages.

A backgrounder is available at the following address: http://media3.marketwire.com/docs/cpha-eng.pdf

NANCHANG, CHINA–(Marketwire – Dec. 3, 2010) – Hiru Corporation (PINK SHEETS:HIRU) (www.hirucorporation.com) subsidiary Shuangshi AHP Co. dispatched company representatives to evaluate the agricultural developments and increase company sales in the regions of Ganzhou, Yichun and Jian.

Shuangshi’s assistant general manager and sales manager met with several potential customers in the aforementioned regions to discuss the potential of Shuangshi products on the local markets, as the company works on gaining more exposure with Chinese farmers for their vaccination needs.

The representatives also negotiated with two new agricultural clients, each client reporting annual sales of approximately $30 million USD. Following these negotiations, Shuangshi AHP representatives supplied the customers with new HIRU products for testing and evaluation by the clients. Shuangshi AHP anticipates to gain more new clients as the company’s top quality animal vaccination products gain exposure in the market.

Safe Harbor Statement

Information in this news release may contain statements about future expectations, plans, prospects or performance of Hiru Corporation that constitute forward-looking statements for purposes of the Safe Harbor Provisions under the Private Securities Litigation Reform Act of 1995. The words or phrases “can be,” “expects,” “may affect,” “believed,” “estimate,” “project” and similar words and phrases are intended to identify such forward-looking statements. Hiru Corporation cautions you that any forward-looking information provided by or on behalf Hiru Corporation is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. Hiru Corporation’s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hiru Corporation’s control. In addition to those discussed in Hiru Corporation’s press releases, public filings, and statements by Hiru Corporation’s management, including, but not limited to, Hiru Corporation’s estimate of the sufficiency of its existing capital resources, Hiru Corporation’s ability to raise additional capital to fund future operations, Hiru Corporation’s ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities, and in identifying contracts which match Hiru Corporation’s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hiru Corporation does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

BURLINGTON, VT–(Marketwire – December 3, 2010) – Marathon Health today announced that C&S Wholesale Grocers, the largest grocery wholesaler in the country, will open an onsite healthcare facility at their headquarters in Keene, N.H. on December 6, 2010.

The C&S Healthy Living Wellness Center, which will be managed by Marathon Health, will serve employees and their families, including dependents over the age of six, within the Brattleboro, VT and Keene, NH area. Available services include acute and primary care, wellness and health promotion, health coaching, disease management, medication dispensing, and the Marathon eHealth Portal technology to support the delivery of care and coaching. The Center staff will include two nurse practitioners, a registered nurse and a medical assistant.

“Marathon Health shares our philosophy about healthcare responsibility and has the tools and programs to help improve the overall health of our workforce,” said Richard Cohen, C&S Chairman and CEO. The worksite healthcare initiative will be offered as part of the company’s Total Rewards health programs that encourage people to be active participants in their own health and healthcare.

“What is most important at Marathon Health is how we inspire people to understand and care about their health — it is the foundation of what we do. We are excited to help C&S enhance the culture of health and responsibility they have established,” said Jerry Ford, Marathon Health CEO.

About C&S Wholesale Grocers

C&S Wholesale Grocers of Keene, NH, is the largest food wholesaler and according to Forbes magazine, the 10th largest privately held company in the United States. The company distributes food to supermarkets, retail stores and military bases across the country.

Currently, C&S serves about 3,900 stores from more than 50 locations in 11 states. Among our customers are many of America’s best known companies, including Stop & Shop, Giant of Carlisle, Giant of Landover, Shaw’s, Great Atlantic & Pacific Tea Co. (A&P), Ralphs, Safeway and Target.

About Marathon Health

Marathon Health of Colchester, VT, offers a proven solution for helping employers reduce the total cost of healthcare. The Marathon Health approach integrates the best practices of onsite primary care, health assessment with risk identification, coaching and advocacy, and disease management for high cost chronic conditions. Marathon Health supports its unique model with an eHealth Portal delivering medical content, interactive diet and fitness tools, a personal health record, and an electronic medical record to manage care. For more information, please visit www.marathon-health.com.

PLEASANTON, CA–(Marketwire – December 3, 2010) – Callidus Software (NASDAQ: CALD)

WHO:

G. F. “Will” Williams, senior incentive compensation analyst, Philips Healthcare

WHAT:

Is your workforce delivering the results that you need? Are they truly aligned with your top-tier business objectives? Learn how best-in-class organizations outperform competitors by using Management-by-Objective (MBO) programs to drive business performance.

WHEN:

Thursday, December 9, 2010

11 a.m. Pacific / 1 p.m. Central / 2 p.m. Eastern Time

WHERE:

To register for the event and for additional information go to:
http://www2.callidussoftware.com/Q410-MBO-Webinar.html

If you cannot attend the live event, please register and we will send you the on-demand version when available.

In the webinar, you will learn:

• Best practices in developing and administering MBOs
• How to develop MBOs that motivate employees and drive them toward accomplishing top-tier corporate objectives
• How to enhance employee engagement
• How to overcome common challenges that can potentially hinder your success

About Royal Philips Electronics

Royal Philips Electronics of the Netherlands (NYSE: PHG) (AMS: PHI), which includes Philips Healthcare, is a diversified health and well-being company, focused on improving people’s lives through timely innovations. As a world leader in healthcare, lifestyle and lighting, Philips integrates technologies and design into people-centric solutions, based on fundamental customer insights and the brand promise of “sense and simplicity”. Headquartered in the Netherlands, Philips employs more than 116,000 employees in more than 60 countries worldwide. With sales of EUR 23 billion in 2009, the company is a market leader in cardiac care, acute care and home healthcare, energy efficient lighting solutions and new lighting applications, as well as lifestyle products for personal well-being and pleasure with strong leadership positions in flat TV, male shaving and grooming, portable entertainment and oral healthcare. News from Philips is located at www.philips.com/newscenter.

About Callidus Software®

Callidus Software (NASDAQ: CALD) is the market and technology leader in Sales Performance Management (SPM). Callidus customers gain a competitive advantage by maximizing sales cost efficiencies and driving improvements in sales effectiveness. Our award-winning Software-as-a-Service (SaaS) applications set the standard for performance management of a company’s sales force and channel partners. Over 2 million employees and channel partners have their performance managed by Callidus Software. For more information, please visit www.callidussoftware.com.

©1997-2010 Callidus Software Inc. All rights reserved. Callidus Software, the Callidus Software logo, and TrueComp Manager are trademarks, service marks, or registered trademarks of Callidus Software Inc. in the United States and other countries. All other brand, service or product names are trademarks or registered trademarks of their respective companies or owners.

Click here to see all recent news from this company

UTICA, NY–(Marketwire – December 3, 2010) – CONMED Corporation (NASDAQ: CNMD), a medical technology company specializing in medical devices for surgical and patient monitoring markets, announced today that the U.S. Food and Drug Administration has given marketing clearance for the Company’s thermal energy based tissue fusion system for use in a wide range of surgical procedures. 

“We look forward to introducing our tissue sealing device, the Altrus® Thermal Tissue Fusion System, to the surgical community,” noted Mr. Joseph J. Corasanti, President and CEO of CONMED. “We believe the current marketplace for energy based instruments approximates $1.5 billion, and while our initial revenue goals for Altrus® in 2011 are modest at $5 – $10 million, we expect Altrus® to be a contributor to our long-term growth prospects.”

Over the last several years, surgeons have expanded the use of energy based instruments to reduce surgical times, improve patient outcomes and decrease procedure costs. Based on CONMED’s original research in the technology, and with the understanding of surgeon needs, CONMED has developed the Altrus® Thermal Tissue Fusion system to advance the performance of energy-based instrumentation. Utilizing thermal energy, the Altrus® System is a multi-functional surgical tool that seals, cuts, grasps, and dissects vessels up to 7mm in size utilizing a closed feedback loop between the energy source and the single-use handpiece to precisely control the desired effect on tissue. Its versatility reduces the need for multiple instruments and instrument changes.

CONMED Profile

CONMED is a medical technology company with an emphasis on surgical devices and equipment for minimally invasive procedures and patient monitoring. The Company’s products serve the clinical areas of sports medicine-arthroscopy, powered surgical instruments, electrosurgery, cardiac monitoring disposables, endosurgery and endoscopic technologies. Surgeons and physicians in a variety of specialties including orthopedics, general surgery, gynecology, neurosurgery, and gastroenterology use the Company’s medical devices. Headquartered in Utica, New York, the Company’s 3,300 employees distribute its products worldwide from several manufacturing locations. 

Forward Looking Information

This press release contains forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties. The forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company’s performance on a going-forward basis. The forward-looking statements in this press release involve risks and uncertainties which could cause actual results, performance or trends, to differ materially from those expressed in the forward-looking statements herein or in previous disclosures. The Company believes that all forward-looking statements made by it have a reasonable basis, but there can be no assurance that management’s expectations, beliefs or projections as expressed in the forward-looking statements will actually occur or prove to be correct. In addition to general industry and economic conditions, factors that could cause actual results to differ materially from those discussed in the forward-looking statements in this press release include, but are not limited to: (i) the failure of any one or more of the assumptions stated above, to prove to be correct; (ii) the risks relating to forward-looking statements discussed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009; (iii) cyclical purchasing patterns from customers, end-users and dealers; (iv) timely release of new products, and acceptance of such new products by the market; (v) the introduction of new products by competitors and other competitive responses; (vi) the possibility that any new acquisition or other transaction may require the Company to reconsider its financial assumptions and goals/targets; and/or (vii) the Company’s ability to devise and execute strategies to respond to market conditions.

BISHOPS STORTFORD, UNITED KINGDOM–(Marketwire – Dec. 2, 2010) – Dotmatics, a provider of information and data management solutions to the life sciences industry, is pleased to announce that it has moved into new UK headquarters. Situated in the centre of Bishops Stortford, The Old Monastery is a historic building (link) built in the 17^th Century.

Stephen Gallagher, Chief Executive Officer of Dotmatics said, “Moving the company to new headquarters marks a new and important milestone for the company. We have seen significant growth in demand for our solutions over the past few years. Expansion into new premises allows us to continue to provide excellent support and development capabilities.”

About Dotmatics

Dotmatics has rapidly emerged as a preferred Informatics supplier to many of the top global Pharma and Biotech organisations. Dotmatics is a scientific software company deploying web-based knowledge solutions that dramatically improve the way scientific data is queried, browsed, managed and shared within companies. Dotmatics has significant expertise in cheminformatics techniques including chemical databases, SAR analysis, data management and data visualization. A privately-owned company, Dotmatics was founded in 2005 and has its head office based south of Cambridge, UK.

Recent Corporate Highlights Include:

Fully web based and searchable ELN launched at EUGM.

http://www.dotmatics.com/news.jsp#id94

Dotmatics opens second U.S. office near Boston Mass.

http://www.dotmatics.com/news.jsp#id93

Heptares Therapeutics chooses Dotmatics platform.

http://www.dotmatics.com/news.jsp#id90

Boehringer Ingelheim license Browser and Vortex.

http://www.dotmatics.com/news.jsp#id81

Spanish Giant Almirall choose Dotmatics for Visualisation

http://www.dotmatics.com/news.jsp#id92

Solution Highlights:

Browser – web-based tool for querying, browsing and visualizing biological databases such as IDBS’ ActivityBase™ and any chemical database.

Vortex – world-class visualization and analytics platform for scientific and non-scientific data.

Gateway – securely enables research teams to share information internally and with external partners.

Pinpoint – powerful Oracle chemical cartridge for querying and integrating chemical databases^*. Pinpoint represents world-class indexing and search performance at a cost-effective price.

Register – flexible and scalable chemical registration system.

Nucleus – map and import biological and non-biological data files into an Oracle database.

Studies – the new standard in screening data management.

Studies Notebook – a web-based ELN for all disciplines.

*Pinpoint is developed in collaboration with Astex Therapeutics Ltd

HUDSON, NY–(Marketwire – December 1, 2010) –
Taconic, un proveedor líder de soluciones de ciencias de la vida para investigadores en todo el mundo, anunció que su programa de producción en Colonia, Alemania obtuvo acreditación de la AAALAC International (la Asociación internacional para evaluación y acreditación de cuidados de animales en laboratorio). Con esta acreditación, todos los programas en el mundo hoy están acreditados AAALAC lo que garantiza a los clientes que Taconic cumple con el más alto estándar de la industria en términos de calidad, salud, integridad genética y cuidados para sus modelos animales.

AAALAC International promueve el tratamiento humanitario de animales en ciencias a través de programas con acreditación y evaluación voluntaria. Taconic fue uno de los primeros proveedores acreditados por la AAALAC International en 1969.

“Desde hace más de cuatro décadas, a través de su participación voluntaria en el proceso de acreditación AAALAC, Taconic ha demostrado su compromiso con el tratamiento humanitario y seguro de los animales de investigación vitales para las ciencias biomédicas de nuestros clientes”, dijo Jeffrey J. Lohmiller, DVM, MS, ACLAM, director global de ciencias veterinarias de Taconic. “El obtener la acreditación AAALAC para todos nuestros programas en todo el mundo es un logro que refleja el enfoque firme de Taconic en calidad y responsabilidad”.

El rigoroso proceso de acreditación requiere una revisión estricta por parte de Taconic y una evaluación exhaustiva en el local por parte de los evaluadores de la AAALAC y una revisión del programa integral de uso y cuidados animales del sitio en Colonia. Para mantener su status de acreditación, todos los programas de Taconic se someten a una reevaluación cada tres años de conformidad con los requisitos de la AAALAC.

Según AAALAC International, más de 800 compañías, universidades, hospitales, agencias gubernamentales y otros instituciones de investigación han obtenido esta prestigiosa acreditación.

Acerca de Taconic
Taconic es un proveedor líder de soluciones de ciencias de la vida para investigadores de todo el mundo, ofrece modelos innovadores de animales de laboratorio y servicios científicos que facilitan estudios “in vivo” y fomentan el descubrimiento de fármacos. La vasta gama de soluciones avanzadas de Taconic comprende el diseño, la generación y la producción de modelos personalizados, los repositorios de modelos comerciales, la caracterización de compuestos, la investigación por contrato, la crianza por contrato, el monitoreo genético y las pruebas de salud. Taconic, con sede en el valle del río Hudson en Nueva York, opera siete plantas de reproducción y crianza y tres laboratorios de servicio en Estados Unidos y Europa y mantiene un personal de más de 1.000 especialistas científicos dedicados a la innovación tecnológica. Información adicional acerca de Taconic está disponible en, www.taconic.com.

HUDSON, NY–(Marketwire – December 1, 2010) –
A Taconic, provedora líder de soluções em vivo para pesquisadores de ciências da vida de todo o mundo, anunciou hoje que o seu programa de produção em Colônia, Alemanha, recebeu a acreditação AAALAC International (Associação Internacional de Avaliação e Acreditação de Cuidado de Animais em Laboratório). Com esta acreditação, todos os programas Taconic em todo o mundo agora são acreditados AAALAC para garantir para os clientes que a Taconic está em conformidade com os mais altos standards de qualidade, saude, integridade genética e cuidado dos seus modelos animais.

A AAALAC International promove o tratamento humano dos animais na ciência através de acreditações e programas de avaliação voluntários. A Taconic foi uma das primeiras fornecedoras a ser acreditada pela AAALAC International em 1969.

“Há mais de quatro décadas, com o nossa participação voluntária no processo de acreditação da AAALAC, a Taconic demonstra a sua dedicação para com o tratamento seguro e humano dos animais de pesquisa que são vitais para a pesquisa biomédica dos nossos clientes”, disse Jeffrey J. Lohmiller, DVM, MS, ACLAM, Diretor Sênior Global de Ciências Veterinárias da Taconic. “A obtenção da acreditação AAALAC em todos os nossos programas do mundo é uma conquista que demonstra o foco inalterável da Taconic na qualidade e responsabilidade”.

O processo rigoroso de acreditação exigiu uma revisão interna por parte da Taconic e avaliação compreensiva no local pelos avaliadores da AAALAC, que fizeram uma análise de todo o cuidado animal e programa de uso nas instalações na Colônia. Para manter o status de acreditada, todos os programas da Taconic passam por uma reavaliação a cada três anos de acordo com as exigências da AAALAC.

De acordo com a AAALAC International, mais de 800 empresas, universidades, hospitais, agências governamentais e outras instituições de pesquisa receberam esta acreditação tão prestigiada.

Taconic
A Taconic é a provedora líder de soluções de ciências da vida para pesquisadores de todo o mundo, oferecendo modelos inovadores de animais de laboratório e serviços científicos que facilitam os estudos in vivo e o avanço da descoberta de medicamentos. Nas soluções avançadas da Taconic estão incluídas a geração e a produção de modelos de ratos e camundongos geneticamente modificados, reprodução de contrato, repositórios de modelos de prateleira, perfis de compostos, pesquisa de contrato, imagem, monitoramento genético e testes de saúde. Com sede no Hudson River Valley em Nova York, a Taconic opera sete locais de reprodução e três laboratórios de serviço nos EUA e Europa, e tem uma equipe de mais de 1.000 especialistas científicos dedicados à inovação tecnológica. Para mais informações sobre a Taconic, acesse www.taconic.com.

POWAY, CA–(Marketwire – December 1, 2010) – Vet-Stem, the world’s leading Regenerative Veterinary Medicine™ company, is pleased to announce a new milestone of 4,000 horses treated with Vet-Stem Cell therapy.

Vet-Stem began providing stem cells to veterinarians in 2004 and has now provided stem cells for the treatment of 4,000 horses. Greater than 75% of horses treated with Vet-Stem Cell therapy for tendon and ligament injuries are able to return to their previous level of performance. What was a new treatment option in 2004 has become the gold standard for performance horses with tendon and ligament injuries.

“We are proud that so many horse owners and veterinarians have placed their trust in Vet-Stem Cell therapy. We feel a great sense of accomplishment knowing that there are thousands of horses and horse owners who have experienced the benefit of stem cell technology. This practical and beneficial application of technology puts stem cell therapy into the present day instead of a future theoretical concept,” said Bob Harman, DVM, MPVM, Founder and CEO of Vet-Stem.

Vet-Stem has also provided stem cells for thousands of dogs with arthritis with a similar success rate. The rapid adoption of stem cell therapy by equine veterinarians and horse owners provided a springboard for use in small animal veterinary medicine. Vet-Stem is now working with small animal veterinarians to develop uses for stem cell therapy for injuries and diseases that currently have few treatment options.

More information about Vet-Stem can be found at www.Vet-Stem.com.

About Vet-Stem, Inc.

Vet-Stem, Inc. was formed in 2002 to bring regenerative medicine to the veterinary profession. In January of 2004, Vet-Stem introduced the first veterinary stem cell service in the United States. The privately held company is working to develop therapies in veterinary medicine that apply regenerative technologies while utilizing the natural healing properties inherent in all animals. Vet-Stem has exclusive licenses to over 50 patents including worldwide veterinary rights for use of adipose derived stem cells.

Click here to see all recent news from this company

MADISON, WI–(Marketwire – December 1, 2010) –  TomoTherapy Incorporated (NASDAQ: TOMO), maker of advanced radiation therapy solutions for the treatment of cancer and other diseases, today announced that it is the exclusive sponsor of the American Cancer Society’s Fall 2010 Matching Grant Challenge, a national fundraising campaign that was launched in November.

As sponsor, TomoTherapy will contribute $1 for every $1 donated by the general public, up to $100,000, to support the American Cancer Society’s efforts to help people stay well and get well from cancer, find cures, and fight back against the disease. The Matching Grant Challenge ends on December 15, 2010.

“Every day, TomoTherapy’s innovative radiation therapy solution helps patients fight cancer. With our support of the American Cancer Society, we extend our impact beyond technology,” said Fred Robertson, M.D., TomoTherapy’s CEO. “In matching the generous contributions of individuals, TomoTherapy proudly strengthens the efforts of the American Cancer Society — from funding groundbreaking research to providing resources for patients, their families and caregivers at every step in the cancer experience.”

About TomoTherapy Incorporated
TomoTherapy Incorporated develops, markets and sells advanced radiation therapy solutions that can be used to treat a wide variety of cancers, from the most common to the most complex. The ring gantry-based TomoTherapy^® platform combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. TomoTherapy’s suite of solutions include its flagship Hi·Art^® treatment system, which has been used to deliver more than three million CT-guided, helical intensity-modulated radiation therapy (IMRT) treatment fractions; the TomoHD^™ treatment system, designed to enable cancer centers to treat a broader patient population with a single device; and the TomoMobile^™ relocatable radiation therapy solution, designed to improve access and availability of state-of-the-art cancer care. TomoTherapy’s stock is traded on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit TomoTherapy.com.

©2010 TomoTherapy Incorporated. All rights reserved. TomoTherapy, Tomo, TomoDirect, TQA, the TomoTherapy logo and Hi·Art are among trademarks, service marks or registered trademarks of TomoTherapy Incorporated in the United States and other countries.

FREMONT, CA–(Marketwire – December 1, 2010) – GammaTech Computer Corp., a major international manufacturer and supplier of innovative notebook and tablet computers, brings its military-grade rugged design and versatile computing to the fast-paced healthcare environment with the MT10L clinical tablet PC. Featuring advanced Intel® Health Mobile Clinical Assistant Solutions reference architecture, a recognized leader in the industry, the MT10L is an ideal mobile solution for healthcare providers searching for an easier way to maintain accurate, timely and instantly accessible records.

“Our MT10L clinical tablet PC is both a simplification and an innovation when it comes to record-keeping for healthcare professionals,” stated Steven Gau, GammaTech president. “Its myriad features allow healthcare workers to make notes in patient-care records at the point of care and document patients’ conditions in real time, ensuring heightened accuracy in documentation. This leads to a reduction in medical errors, enhanced workflow, faster, safer patient care, better transcription efficiencies, better insurance practices and more accurate billing.”

At under three pounds, with a slim, clipboard-style design and molded ergonomic handle, the GammaTech MT10L clinical tablet PC is easy to carry and hold during those long shifts. The 10.4″ high-resolution (1024×768) XGA TFT LCD display features brightness adjustment, eliminating eyestrain, while the resistive touchscreen responds to both fingertips and the included stylus pen. Your shift will never be interrupted by the need to recharge, as hot-swappable twin battery packs provide up to eight hours of life. The fully sealed fan-less design offers ingress protection to guard internal components. In an environment where technology is susceptible to damage from slips and liquids, the MT10L is military-grade in its durability: the fully sealed design ruggedly protects internal components, making the tablet drop-proof, spill-proof, shock-proof, dust-proof, watertight and alcohol and disinfectant wipe resistant (to protect against cross contamination).

Recording patients’ progress as it happens is a snap — literally. The MT10L’s two-megapixel camera with auto-focus enables quicker, more detailed documentation of wounds, surgical sites, range of motion and other conditions, and photos can be saved directly to a patient’s electronic medical record. The MT10L is specifically designed to take advantage of all the features and innovations inherent in Electronic Medical Record advancements. Furthermore, the introduction of this line advances the fiscal incentive programs offered by the Federal government in order to promote electronic healthcare record adoption by clinicians and healthcare facilities. Other features include a docking station, AC power connector, built-in RFID reader and a barcode reader to help reduce prescription errors.

The GammaTech MT10L clinical tablet PC supports both Wi-Fi and Bluetooth technologies and runs on Windows 7 Professional, Vista Business and XP Tablet Edition operating systems.

Availability
The MT10L — along with the entire GammaTech product line — is available to healthcare professionals, hospitals, group purchasing organizations, government entities and universities through authorized GammaTech resellers nationwide. For more information, please visit www.gammatechusa.com.

About GammaTech Computer Corporation
For over two decades, GammaTech Computer Corporation is a leader in the design, manufacturing and sales of rugged and hardened notebook and tablet computers throughout North America. GammaTech promotes its award winning, built-to-order durable mobile computers to businesses, government, healthcare, fire, law enforcement and public safety entities. GammaTech is headquartered in Fremont, California, which provides the final assembly, inventory, service and technical support.

For more information, please visit GammaTech at www.GammaTechUSA.com.

All products/services and trademarks mentioned in this release are the properties of their respective companies.
© 2010 GammaTech Computer Corporation. All rights reserved.

Click here to see all recent news from this company

HUDSON, NY–(Marketwire – December 1, 2010) – Taconic, a leading provider of in vivo solutions to life science researchers worldwide, announced that its Cologne, Germany production program has earned accreditation from AAALAC International (the Association for Assessment and Accreditation of Laboratory Animal Care International). With this accreditation, all Taconic programs worldwide are now AAALAC accredited thereby assuring customers that Taconic meets the highest industry standard of quality, health, genetic integrity and care for its animal models.

AAALAC International promotes the humane treatment of animals in science through voluntary accreditation and evaluation programs. Taconic was one of the first suppliers to be accredited by AAALAC International in 1969.

“For more than four decades, through our voluntary participation in the AAALAC accreditation process, Taconic has demonstrated its commitment to the safe, humane treatment of the research animals that are vital to our clients’ biomedical research,” said Jeffrey J. Lohmiller, DVM, MS, ACLAM, Global Senior Director, Veterinary Sciences, Taconic. “Attaining AAALAC accreditation across all of our programs worldwide is an achievement that reflects Taconic’s unwavering focus on quality and accountability.” 

The rigorous accreditation process required both a stringent internal review by Taconic and a comprehensive, on-site assessment by AAALAC evaluators, reviewing the Cologne site’s entire animal care and use program. To maintain their accredited status, all Taconic programs undergo re-evaluation every three years as per AAALAC requirements.

According to AAALAC International, more than 800 companies, universities, hospitals, government agencies and other research institutions have earned this prestigious accreditation.

About Taconic
Taconic is a leading provider of life sciences solutions to researchers worldwide, offering innovative lab animal models and scientific services that facilitate in vivo studies and advance drug discovery. Taconic’s wide range of advanced solutions include custom genetically modified rat and mouse model generation and production, contract breeding, off-the-shelf model repositories, compound profiling, contract research, imaging, genetic monitoring and health testing. Headquartered in New York’s Hudson River Valley, Taconic operates seven breeding facilities and three service laboratories in the U.S. and Europe and maintains a staff of over 1,000 scientific specialists committed to technological innovation. Additional information about Taconic is available at www.taconic.com.

SPARTA, NC–(Marketwire – December 1, 2010) – Amano Pioneer Eclipse^® (“APEC”), a worldwide manufacturer of professional floor care products, makes it easy to be green even when cleaning carpets. Their EnviroStar Green^® carpet care system is an effective and cost saving method to meet many of today’s green requirements. The system is comprised of four products — a dual purpose extractor & pre-spray cleaner, an extraction rinse, a soil release bonnet buff and an all purpose spotter. 

APEC chemists developed EnviroStar Green from specific raw ingredients that met specific green requirements. The benefits of using the EnviroStar Green system however, go well beyond meeting strict environmental standards. “Our green products are not only earth friendly, they also reduce certain ill effects produced by other conventional systems,” states Jacqueline Van Delft, VP of International Operations at Amano Pioneer Eclipse. “We use raw ingredients that are not classified as skin sensitizers to lower irritancy commonly found in traditional chemistry. This produces a more comfortable and healthier environment for everyone.”

Most traditional cleaning processes leave some residue on the carpet. Not only can this residue trigger allergic reactions in many people, it also affects future maintenance and replacement costs. Acting like glue, residue can quickly attract new dirt to a recently cleaned floor. Commonly known as resoiling, this dirt build-up leads to more frequent cleanings that shorten the life of the carpet.

To minimize residue, Amano Pioneer Eclipse formulated EnviroStar Green products with pH levels less than 10. Compared to some traditional carpet products with levels as high as 11 to 13, a more neutral pH allows more of the chemical to be extracted, is less damaging to carpet fibers and retains existing stain blocking treatments that extend the carpet’s life. 

The EnviroStar Green carpet care system does more than reduce the environmental impact of traditional cleaning. Competitively priced, these products lower downtime and maintenance costs, extend carpet life, reduce cleaning frequency and improve the health and safety of the surrounding environment. And, most of all, they produce results as good as or better than their more harmful counterparts. It’s no wonder that professionals around the world are turning to Amano Pioneer Eclipse for all their carpet care chemicals. For more information on EnviroStar Green Carpet Products and numerous other Amano Pioneer Eclipse floor care systems, please visit www.pioneer-eclipse.com. In the US call 1-800-367-3550. For international inquires call 1-336-372-8080.

About Amano Pioneer Eclipse – since 1978, Amano Pioneer Eclipse has provided building service contractors with mechanical and chemical solutions for cleaning and maintaining all types of flooring.

Click here to see all recent news from this company

TAMPA, FL–(Marketwire – December 1, 2010) – Sage Healthcare Division, a unit of Sage North America and a major provider of EHR and practice management software and solutions serving approximately 80,000 physicians in North America, today announced that Northwest Primary Care, a 25 physician, physician-owned practice in southeast Portland, has selected Sage to provide the IMPAX PACS (picture archiving and communication system). This new medical imaging system will augment the practice’s existing Sage Intergy practice management and EHR system. 

Sage Healthcare Division offers the IMPAX, a comprehensive PACS, through an arrangement with Agfa HealthCare. The IMPAX solution will allow Northwest Primary Care to more efficiently manage its growing medical imaging services and improve efficiency in reading and reporting on medical imaging studies.

Northwest Primary Care is moving away from film and chose the PACS through Sage to improve patient care and increase quality outcomes, said administrator Michael Whitbeck. “We sought a sophisticated PACS system that will allow our radiologists and physicians to look at the film right from the record, and to allow for more mobility of our radiologists who will be able to view film from anyone, on or off site,” Whitbeck said.

PACS also will reduce the need for redeveloping images related to over and under exposed film, a common problem with film images, said Whitbeck. “We’ll be able to alleviate those issues with PACS, and from that perspective, improve overall quality of care for patients,” he said. 

Northwest Primary Care has four locations throughout southeast Portland, Oregon, and hosts more than 81,000 patient visits per year. In addition to implementing the Agfa HealthCare PACS system through Sage, it has used Sage Intergy EHR for its practice management and electronic health records since 2006. Sage Intergy EHR is fully compatible with the Agfa HealthCare PACS solution, and allows for the viewing of patient images through the EHR. Sage Intergy EHR also can integrate its Radiology Information Systems (RIS) with the Agfa HealthCare solutions.

“Sage remains dedicated to its clients and committed to health centers such as Northwest Primary Care because of the trust they place in our products to improve health outcomes for patients,” said Betty Otter-Nickerson, president of Sage Healthcare Division. “Providing a multitude of solutions, such as an integrated PACS solution to go along with our EHR, shows our dedication to improving practice efficiency and remaining true to our mission of being physician focused and patient centric.”

Sage is a reseller of the Agfa HealthCare PACS and Computed Radiology (CR) solutions and offers installation of the PACS software, along with user support and training.

Sage has provided healthcare software solutions to streamline patient care for nearly 30 years, and is a leading supplier of business management software and services, serving more than 6.2 million small and midsized business customers worldwide.

View Sage Healthcare Division YouTube interviews.

View Sage Healthcare Division information.

About Sage Healthcare Division
Sage Healthcare Division provides integrated electronic health records, EDI applications and practice management systems to approximately 80,000 physicians and thousands of ambulatory care practices throughout North America. These systems enable physicians and practice managers to better manage their practices and improve profitability. Sage Healthcare Division is based in Tampa, Fla., and is a division of Sage North America. For more information, please visit www.sagehealth.com or call (877) 932-6301.

About Sage North America
Sage North America is part of The Sage Group plc, a leading global supplier of business management software and services. Sage North America employs 4,000 people and supports 3.2 million small and midsize business customers. The Sage Group plc, formed in 1981, was floated on the London Stock Exchange in 1989 and now employs 13,400 people and supports 6.3 million customers worldwide. For more information, please visit the website at www.sagenorthamerica.com.

© 2010 Sage Software, Inc. All rights reserved. Sage, the Sage logos, and the Sage product and service names mentioned herein are registered trademarks or trademarks of Sage Software, Inc. or its affiliated entities. All other trademarks are the property of their respective owners.

SCOTTSDALE, AZ–(Marketwire – December 1, 2010) – The holidays are the perfect time to show loved ones just how much you care. This year give your family and friends the miCARD Gift Card. The only holiday gift card that could save their life in a medical emergency.

At $14.95, the miCARD Gift Card (www.micard.com/migift) is the perfect stocking stuffer to help ensure the health and safety of those you care about most. miCARD’s wallet card gives first responders a readable summary of a loved one’s vital medical information 24/7, worldwide. In less than one minute, miCARD ensures that medical personnel have the essential information they need to make lifesaving decisions from any location. The miCARD Gift Card can be created securely online and is offered as either a printed gift certificate or it can be emailed for those hard-pressed to meet holiday postal deadlines.

“The holiday season reminds us of how much we care about family and friends. Most of us would do anything to ensure their health and safety,” said Dr. James Kelley, a practicing ER physician and co-founder of miCARD. “We wanted to create a holiday gift that offered real value and could actually save lives. Carrying medical information is a proactive step that could both improve your care and save your life.”

Are You Prepared for a Medical Emergency?
1 in 3 Americans will experience a medical emergency this year, yet most of us carry nothing that describes our unique medical background or identifies loved ones to contact in the event of a medical emergency. It’s critically important that individuals of all ages organize and manage their personal medical information in preparation of an unexpected medical event.

miCARD is the only medical information card and online Personal Health Record designed by an emergency physician. miCARD’s wallet card is designed to provide emergency personnel, in the field, a readable summary of a users vital medical information such as: medical conditions, critical medications, emergency contacts, allergies and more. The portable medical card is further supported by an online Personal Health Record containing additional medical information: advance directives, physician contacts, EKG, lab results, and current medications. All personal medical information is stored securely online and viewable at the miCARD website 24/7 by treating medical providers worldwide.

miCARD’s Holiday Gift Card is a low cost solution to the problem of emergency preparedness and care. To order your miCARD Gift Card visit www.micard.com/migift

About miCARD®
miCARD® is a physician-designed, medical information card and online Personal Health Record designed to optimize emergency medical care. miCARD’s proprietary solution improves the flow of critical care information and ensures medical personnel have immediate and secure access to a user’s vital medical information 24/7, worldwide. For more information about miCARD, please visit www.micard.com or contact us at (866) 596.2956.

Click here to see all recent news from this company

TOLEDO, OH–(Marketwire – December 1, 2010) – Cardiothoracic Surgeons for Northwest Ohio and The Toledo Hospital are now in the nation’s top 12% of hospitals for heart surgery. This is according to a three-star comprehensive rating system, developed by The Society of Thoracic Surgeons (STS), which compares the quality of heart surgery in hospitals across the country. A three-star rating is the highest designation that a hospital can attain for quality and clinical excellence. Cardiothoracic Surgeons for Northwest Ohio was compared to more than 1,000 surgical groups.

Hospitals are scored on performance in the following four categories — patient survival, absence of surgical complications, recommended medications, and optimal surgical technique. The ratings reflect results from isolated heart-bypass operations called coronary artery bypass grafting to newer versions, which include minimally invasive bypass and other complex cardiac procedures.

“I am grateful to my partners and colleagues at The Toledo Hospital who have worked diligently for years to reach this incredible milestone,” said Michael Moront, MD, senior partner, Cardiothoracic Surgeons for Northwest Ohio. “When patients enter our doors, they can feel confident that they will be receiving the very best care from one of the nation’s leading medical groups.”

Consumers can easily see how surgical groups compare with national benchmarks for survival, complications, and other measures by visiting www.consumerhealthreports.org.

About STS
The Society of Thoracic Surgeons is a not-for-profit organization representing more than 6,000 surgeons, researchers and allied health care professionals worldwide who are dedicated to ensuring the best possible outcomes for surgeries of the heart, lung, and esophagus as well as other surgical procedures within the chest. Founded in 1964, the mission of STS is to enhance the ability of cardiothoracic surgeons to provide the highest quality patient care through education, research, and advocacy. Its National Adult Cardiac Surgery Database includes more than 4 million surgical records and covers roughly 90% of the more than 1,000 surgical groups in the U.S. that perform cardiac surgery, making it the largest such registry in the world.

About Cardiothoracic Surgeons for Northwest Ohio
Cardiothoracic Surgeons for Northwest Ohio is a member of ProMedica Heart and Vascular Institutes, a collaboration of physicians, technology and specialty services. The group provides a comprehensive scope of leading edge patient care and state-of-the-art surgical procedures, including minimally invasive procedures, bloodless surgery, pediatric cardiac surgery, aortic valve repair and replacement and more. Its team of board-certified physicians, specialists and medical staff make up the largest cardiothoracic surgical program in northwest Ohio.

For more information about cardiac services at ProMedica Health System, visit www.promedica.org.

Cardiothoracic Surgeons for Northwest Ohio and The Toledo Hospital are members of ProMedica Health System. ProMedica, a mission-based organization, was formed in 1986 and is a Toledo, Ohio-based, not-for-profit healthcare organization with more than 14,000 employees; 3,000 physicians and more than 306 facilities in Ohio and Michigan. ProMedica serves more than 2.73 million patients annually and includes 11 hospitals; ProMedica Continuum Services with senior, hospice, rehabilitation, and integrative services; ProMedica Physician Group, a network of more than 315 primary care and specialty physicians; and Paramount Health Care, the largest HMO in northwest Ohio. For more information, please visit www.promedica.org.

TRAVERSE CITY, MI–(Marketwire – December 1, 2010) –  Just ten weeks after Versus Technology, Inc. (Versus) (PINKSHEETS: VSTI) was selected to support the Bethesda Hospitals’ Emergency Preparedness Partnership (BHEPP) Real-time Locating System (RTLS) initiative, the Versus Advantages^™ system was recently utilized during the organization’s disaster preparedness drill.

The October 14, 2010 drill was the sixth annual Collaborative Multi-Agency Exercise (CMAX-10) since the BHEPP was formed in 2004, and the first to utilize RTLS for continuity of patient information. Participating organizations included Suburban Hospital, Johns Hopkins Medicine, the National Naval Medical Center (both trauma centers), the U.S. NIH Clinical Center, and the National Library of Medicine. The drill was designed to test the medical readiness and response proficiency supposing a mass casualty in the National Capital Region. Surge capabilities and patient tracking were key components to be tested.

The BHEPP began exploring RTLS options after the inability to track patients during a mass casualty event had been documented as a gap in multiple real disasters. The U.S. Navy produced a video for CMAX-09, in which, Brian Grangnolati, President, Suburban Hospital states, “If you think about what the biggest problem is in any crisis, it’s communication and moving information” as he explains the need for RFID / RTLS. Versus’ RTLS was selected to enhance communication and keep information tied to patients, even as they are moved from facility to facility.

The BHEPP’s goal is to create a sustainable response model that can be replicated in other areas, especially densely populated areas at risk for national disasters or terrorist attacks. “Having real-time information related to the victim’s arrival and location was immensely helpful to the first-time Incident Commander in his decision making,” says Cindy Notobartolo, Division Director ED/Trauma, Safety & Security Services at Suburban Hospital. “Within our patient information system, the patient’s location was tied to triage and treatment data and made available in real-time to all emergency care personnel. The external evaluators were impressed that our tracking ability was 100% throughout the exercise.”

During the drill, as victims arrived at Suburban Hospital triage area, they were decontaminated, triaged and assigned Versus ID badges which were worn clipped to the victim’s clothing. A photo of the victim was also taken to support Lost Person identification and family reunification efforts. Emergency personnel then transported the patient to the appropriate treatment area.

The Versus ID badges, which emit digitized infrared (IR) and radio-frequency identification (RFID) signals, immediately communicated the patient’s location and triage level to care providers and Central Command via the BHEPP’s patient information system. When patients were reassessed, treated or moved to other areas, their locations were updated in real-time. Location of key personnel and equipment was also provided in real-time.

Versus prepared views and rules to support the key RTLS drill functionality as outlined below.

1. Real-time locating of all patients from decontamination and triage through discharge or hospital admission. 
2. Rules-based pediatric monitoring, with location-based alerts to help ensure children are secure and monitored at all times. The CMAX-10 drill did not take advantage of the dedicated pediatric area; however, the rules for monitoring and securing pediatric patients are in place and fully functional for future use. 
3. Real-time locating of critical equipment to decrease time to locate, improve utilization and support sharing across participating facilities. 
4. Web service integration with National Library of Medicine’s Patient Tracker for badge assignments, triage level and patient demographic information as it became available to the provider.
5. Real-time locating of key mass casualty incident personnel to improve communication and enhance decision-making capabilities of the Incident Commander. 
6. Tracking the evacuation of current hospital patients and their arrival at remote partner facilities for expanded surge capacity.

CMAX-10 was a valuable exercise for both the BHEPP and Versus; each organization identified areas for improvement related to expanded use, patient identification, training, information availability, advanced rules for patient transfer and make-ready operations. They look forward to building on this foundational experience to enhance communication and safety during future drills and in the event an actual response is required.

About BHEPP
This partnership is a first-of-its-kind collaboration that links military, federal, local and private mass disaster medical response efforts within the national capital area. Established in 2004, the partnership is now a model for other health care agencies throughout the country.

About Versus Technology, Inc.
Established in 1988, Versus Technology, Inc. specializes in real-time location systems (RTLS) for healthcare. Used for enterprise patient tracking, bed management, asset tracking, and nurse call automation, Versus Advantages™ improves patient flow and documentation of caregiver and patient interactions, while enhancing communication and efficiency. Exclusively endorsed by the American Hospital Association, the Versus Advantages infrared (IR) and Active RFID solution is responsible for clinical-grade location and automation at a number of hospitals, clinics and long-term care facilities worldwide. To learn more about Versus Technology, Inc. (PINKSHEETS: VSTI), our technology and client successes, visit www.versustech.com and take the Advantages Tour.

Safe Harbor Provision
This release may include forward-looking statements which “bespeak caution,” and which are subject to risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. The statements are made only as of the date of this release, and the Company undertakes no obligation to update them to reflect subsequent events or circumstances.

Click here to see all recent news from this company

ATLANTA, GA and BOSTON, MA–(Marketwire – December 1, 2010) – LumaMed LLC has entered into an initial agreement with Massachusetts General Hospital to commercialize an imaging system developed at the Wellman Center for Photomedicine that could revolutionize cancer surgery.

The technology is complementary to that previously licensed by LumaMed from Providence Hospital in Oregon for teledermatology imaging, and has the demonstrated ability to provide real-time surgical guidance, enabling a surgeon to “see” cancer margins.

LumaMed’s cancer imaging technology addresses an estimated $1 billion market opportunity for products that improve efficiency and efficacy in cancer removal procedures. Cancer margin delineation is critical in instances where tissue preservation is important, including skin, head and neck, breast, prostate and brain surgeries.

LumaMed is initially focusing on skin cancer, which is the most common of all cancers. Each year, over one million new cases of skin cancer are detected and many require painstaking and expensive Mohs surgery. Once cleared by the FDA, LumaMed plans to market the new devices to Mohs skin cancer surgeons as a visual aid to help eliminate the need for more than one surgical stage, thus improving patient care and creating a substantial economic benefit.

“In combination with a trained physician, we believe LumaMed’s technology could complement histopathological evaluation, help accurately define margins and reduce the occurrence of biopsies,” said Mark A. Samuels, chief executive officer of LumaMed. “The technology agreement with Massachusetts General Hospital will provide us with the additional tools necessary for development and commercialization of our image-guided surgical systems for the real-time evaluation of skin lesions and other cancers.”

LumaMed is combining two powerful approaches for rapid, easy and cost-effective onsite and remote evaluation of suspicious skin lesions using polarization-based spectroscopic imaging technology. Called “Polarization Subtraction Imaging,” PsiScan technology selectively samples the dermal/epidermal junction and papillary dermis, where cancer originates, and enhances image clarity by rejecting surface scatter and light from deeper layers. This results in images with significantly greater clarity and contrast for improved tumor identification and margin delineation. Clarity and contrast is required in skin cancer evaluation to recognize the disruption of the rich texture of the papillary dermis or to detect tumor silhouettes that identify basal cell carcinomas. Such disruption is difficult to discern with existing dermatoscopes or point-and-shoot digital cameras.

About LumaMed, LLC.
LumaMed is developing devices that provide rapid, easy and improved imaging of cancer based on patented “Polarization Subtraction Imaging” (PSI) technology. LumaMed’s revolutionary cancer visualization tools enable real-time imaging of cancer margins during surgery with an accuracy approaching that of conventional pathology. In addition to the initial focus on skin cancer, the approach can be used with other cancers such as prostate, breast, and head and neck cancers. LumaMed products have not been cleared by the FDA for sales in the U.S. and are not presently being offered for sale. For more information, visit www.lumamed.com.

VANCOUVER, BRITISH COLUMBIA–(Marketwire – Dec. 1, 2010) – Premier Diagnostic Health Services Inc. (CNSX:PDH) (“PDH”) announces the offering of two non-brokered term sheets to raise a total of $350,000.

The two non-brokered term sheets: “Offering A” and “Offering B” are offered to accredited investors.

1. Offering A consists of 625,000 Units at $0.40 per Unit, each Unit consisting of one Share and one half Warrant, with a minimum subscription of 125,000 Units for $50,000, for a total Offering of $250,000. One Half Warrant is included with each Unit; a full Warrant entitles the holder to subscribe for a further Share of PDH for $0.60 per Share. Warrants will be non-transferable and will expire on June 30, 2011.

2. Offering B consists of 250,000 Shares of Premier Diagnostic Health Services Inc. (“PDH”) to raise a total of $100,000. The price per Share is $0.40.

Both “A” and “B” Offerings will expire at 5:00 p.m. on December 20, 2010.

The proceeds from the term sheets will be used to:

1. Identify a second hospital in the metropolitan area of Beijing, China (in addition to PDH’s already established Center), for the establishment and joint operation of a Center for Advanced Diagnostics using PET-CT scanning for the diagnosis of cancer, with the objective of entering into a definitive agreement within three months;
2. Identify between one and three hospitals in the Pearl River Delta region of Guangdong province, China, particularly in the metropolitan area of Guangzhou, for the establishment and joint operation of Centers for Advanced Diagnostics using PET-CT scanning for the diagnosis of cancer, with the objective of entering into definitive agreements within six months; and
3. General working capital purposes.

The non-brokered private placement offering announced November 3, 2010 was not proceeded with.

About Premier Diagnostics Health Services Inc. (CNSX:PDH)

As leaders in advanced health and education with the international medical community, PDH is rolling out its global strategy of establishing a network of Centres for Advanced Diagnostics in Canada and China. By utilizing MRI and PET-CT, the most advanced medical diagnostic imaging technology available and the production of FDG, the radiopharmaceutical tracer used in oncology PET procedures; PDH is uniquely positioned to deliver continued innovation, growth and profitability.

UTICA, NY–(Marketwire – November 30, 2010) – CONMED Corporation (NASDAQ: CNMD), a medical technology company specializing in medical devices for surgical and patient monitoring markets, announced today that the Company has amended its existing senior credit facilities to provide for a five-year, $250 million senior secured revolving credit facility. The term loans currently outstanding will remain in place. A group of ten financial institutions have agreed to participate in the revolving credit facility, with JP Morgan Chase Bank, N.A. as Administrative Agent. The revolving credit facility was arranged by J.P. Morgan Securities LLC and Merrill Lynch, Pierce, Fenner & Smith Incorporated (successor by merger to Banc of America Securities LLC) as joint lead arrangers and joint bookrunners.

The amendment increases the revolving line of credit to $250 million and extends its term to November 30, 2015. Interest on drawn amounts is based on a pricing grid determined by the Company’s senior secured debt leverage ratio. At the present leverage ratio, interest cost is equal to LIBOR plus 1.75% and the fee on undrawn commitments is equal to 25 basis points. The agreement also permits a $75 million expansion of the revolver with consent of lenders participating in the expansion.

“We are pleased that our bank lenders have provided this increased credit facility with terms we consider favorable to CONMED,” said Mr. Joseph J. Corasanti, President and Chief Executive Officer. “We do not anticipate that interest expense will be materially affected by the new revolver.”

The new facility will be used to refinance the existing $49 million outstanding on the previous revolving credit facility, eliminate the previous receivable financing facility and for general corporate purposes. It is also intended to provide liquidity should the Company be required to fund the $112 million face amount of 2.5% Senior Subordinated Notes which are puttable on November 15, 2011. 

CONMED Profile

CONMED is a medical technology company with an emphasis on surgical devices and equipment for minimally invasive procedures and patient monitoring. The Company’s products serve the clinical areas of sports medicine-arthroscopy, powered surgical instruments, electrosurgery, cardiac monitoring disposables, endosurgery and endoscopic technologies. Surgeons and physicians in a variety of specialties including orthopedics, general surgery, gynecology, neurosurgery, and gastroenterology use the Company’s medical devices. Headquartered in Utica, New York, the Company’s 3,300 employees distribute its products worldwide from several manufacturing locations.

Forward Looking Information

Certain statements made herein constitute forward-looking statements. The forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company’s performance on a going-forward basis. They are based upon management’s expectations and involve risks and uncertainties which could cause actual results, performance or trends, to differ materially from those expressed in the forward-looking statements therein or in previous disclosures. The Company believes that all forward-looking statements made by it have a reasonable basis, but there can be no assurance that management’s expectations, beliefs or projections as expressed in the forward-looking statements will actually occur or prove to be correct. In addition to general industry and economic conditions, factors that could cause actual results to differ materially from those discussed in the forward-looking statements include, but are not limited to: (i) the failure of any one or more of management’s assumptions to prove to be correct; (ii) the risks relating to forward-looking statements discussed in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and Quarterly Reports on Form 10-Q; (iii) cyclical purchasing patterns from customers, end-users and dealers; (iv) timely release of new products, and acceptance of such new products by the market; (v) the introduction of new products by competitors and other competitive responses; (vi) the possibility that any new acquisition (and its integration) or other transaction may require the Company to reconsider its financial assumptions and goals/targets; (vii) increasing costs for raw material, transportation, or litigation; and/or (viii) the Company’s ability to devise and execute strategies to respond to market conditions.

AUSTIN, TX–(Marketwire – November 30, 2010) – ProAssurance Corporation (NYSE: PRA) today completed its previously announced acquisition of American Physicians Service Group, Inc. (“APS”) (NASDAQ: AMPH). As a result of the merger, APS is now a wholly-owned subsidiary of ProAssurance.

The Chairman and Chief Executive Officer of APS, Ken Shifrin, said, “We’ve found the ideal partner to carry on the physician-focused traditions of APS. We know that ProAssurance will continue to serve our 6,800 insureds with the individual attention that is a part of our mutual corporate cultures. The last decade has resulted in a spectacular 36% average annual increase in APS’ stock price, from $1.50 to $32.50, and I want to thank our shareholders for their trust and for the opportunity to lead the company during this exciting time. I also want to say what an honor it has been to work with the board of directors and employees of APS and to thank them for their loyalty and dedication.”

“We are excited about the opportunities this transaction creates for us,” said ProAssurance’s Chairman and Chief Executive Officer, W. Stancil Starnes. “Not only does it give us significant market presence as the second largest writer of medical professional liability (MPL) insurance in Texas, it also enhances our presence in Oklahoma and Arkansas. We expect to leverage the skill and dedication of APS’ employees to deliver an unmatched level of service and financial strength to policyholders in these three key states. Additionally, we believe our shareholders will see benefits as well, as we expect to grow profitably during a challenging time in our business.”

Under the terms of the merger, each share of APS stock was redeemed for $32.50 in cash. Shareholders whose stock is held by a broker or in direct registration will be paid automatically. Those APS shareholders with stock certificates will receive instructions by mail for surrendering their shares in order to receive payment. Shareholders with questions about the share conversion process may contact American Stock Transfer & Trust at (877) 248-6417.

As a result of this transaction, APS’ common stock will cease to trade on the Nasdaq Stock Market prior to the open of business on December 1, 2010, and will thereafter be delisted.

About APS

APS is an insurance holding company with subsidiaries that provide medical malpractice insurance for physicians and other healthcare providers. APS is headquartered in Austin, Texas. Further information about the company is available on the Internet at www.amph.com.

PRINCETON, NJ–(Marketwire – November 30, 2010) –  To assist companies in managing their healthcare insurance options and show third party administrators (TPA), insurers and physicians how to react appropriately, Health Options Worldwide (HOW), an online vacation surgery resource, is offering a free webinar. Titled “Health Care Trends and Employers: New Strategies for a Changing Marketplace,” the webinar takes place Thursday, December 2nd, at 10 am EST and 4 pm EST. HOW, an international and domestic medical travel and medical tourism agency, will cover the current state of the healthcare marketplace as well as value-based and competitively priced key service to businesses.

Participants can register for 10am EST: https://www3.gotomeeting.com/register/526273158

Participants can register for 4pm EST: https://www3.gotomeeting.com/register/505357078

If participants have any questions or problems registering for the webinar, please contact Chris Peterson at 1-877-234-1345 or via email at: [email protected]. For more information, visit the HOW website at: www.healthoptionsworldwide.com

“Due to rising healthcare costs, companies need new strategies to reduce healthcare spending, improve the quality of care, and educate employees to take a more active role in their healthcare. Employers are afraid of the high costs that come with a self-funded employer solution, but yet they still want to provide health insurance coverage for their employees,” said David Goldstein, president of HOW.

Words like high deductible health plan surgery and voluntary surgery networks will become very popular in the healthcare market. As employee benefits claims and costs continue to rise, employers, TPAs and doctors can benefit from this webinar, says Goldstein. Employers can learn new ways to control risk and encourage employees to become more proactive in managing their healthcare and healthcare spending.

Current healthcare reform stipulations have not reduced claims or costs. Inflation, increased use of services, aging population, changes in provider treatment patterns, medical technology and drug therapy improvements have also influenced the upward healthcare spending trend. “The cost of employer health plans will probably increase within the next six months,” said Goldstein, quoting a survey by Wells Fargo Insurance Services.

Value based healthcare plans and supplemental healthcare solutions are affordable coverage options for businesses that can benefit workers. An increasing number of employers are researching different types of health insurance plans for their employees, knowing they can help them in many different ways.

“HOW leverages the growing trend of consumer-driven health care by connecting patients with physicians that offer high quality, low cost healthcare in the United States as well as internationally,” said Goldstein. He continued by saying that medical tourism will definitely affect the next generation of PPO’s by giving employees more local and regional treatment options with substantial discounts and improved outcomes.

Click here to see all recent news from this company

ATLANTA,GA–(Marketwire – November 30, 2010) – Clinigence, LLC, a health information technology company focused on the development of clinical business intelligence tools for accountable care organizations (ACOs) and healthcare providers, today announced that Steven M. Ornstein, M.D. has joined the Clinigence Advisory Board overseeing the development of the Clinigence collaborative software-as-a-service (SaaS) platform, helping care providers deliver quality care cost-efficiently.

Dr. Ornstein is a professor at the Department of Family Medicine and Graduate Studies at the Medical University of South Carolina (MUSC) in Charleston. He is also the founder and director of the Practice Partner Research Network (PPRNet) — the nation’s oldest and one of the largest practice-based research networks, operating for over 15 years and covering over 140 practices, 740 care providers and 1.8 million patients in 38 states.

Dr. Ornstein received his BA degree from Dartmouth in 1978 and his MD degree from Duke in 1981. He completed his residency in family practice at MUSC in 1985. He is board certified in family practice and has practiced continuously at MUSC Medical Center since 1985. Dr. Ornstein is a member of the American Academy of Family Physicians. He has led and participated in dozens of research studies on improving the quality of care through prevention, patient engagement and adherence, evidence-based guidelines and the use of information technology. At PPRNet, Dr. Ornstein has pioneered and perfected the translation of research into clinical practice to achieve real, measurable improvements in patient care.

“We are extremely pleased to welcome Dr. Ornstein to our advisory board,” said Kobi Margolin, Clinigence’s CEO. “We believe that his depth of knowledge in the area of translating scientific evidence into real-life improvement in patient outcomes will help us achieve the full potential of our unique and timely clinical business intelligence platform.”

About Clinigence

Clinigence, LLC, in Atlanta, is a health information technology company. Conceived in 2009 and launched in 2010, Clinigence develops, publishes and delivers collaborative software-as-a-service (SaaS) to help healthcare providers derive business value from clinical data and quality patient care. The Clinigence solution is tailored to the emerging needs of healthcare providers due to the shift of the US healthcare system from volume- to value-based purchasing and the growing demand for quality patient care. More information can be found at http://www.clinigence.com or contact Kobi Margolin at [email protected] or +1-678-466-6650.

CINCINNATI, OH–(Marketwire – November 30, 2010) –  “Using Benchmarks: The Good, The Bad, and The Ugly,” a new guide from Compass Clinical Consulting authored by Shawna O’Neill, RN, MHA; Eric Dam, MHA and Compass Clinical President Cary Gutbezahl, MD, reveals the positives and negatives of hospital benchmarking.

THE BENCHMARKING PROBLEM — ONE-DIMENSIONAL MEASUREMENT

Measurement is the cornerstone of assessing the performance of a hospital department. But, the problem is that benchmarks are one-dimensional, while real work is not. Designing productivity processes using benchmarks can cause problems if not done correctly.

BUILDING A CULTURE OF PRODUCTIVITY

“Using Benchmarks: The Good, The Bad, and The Ugly” shows how hospital leaders and managers can employ benchmarks to build a culture of productivity and provides strategies to:

• Help struggling managers meet their productivity targets while gaining buy-in from staff members
• Optimize workforce productivity using realistic benchmarks as guidelines, not mandates
• Ensure that leaders, managers, and employees “speak the same language” by establishing common definitions of key terms
• Create appropriate staffing levels to meet department workloads

ADD VALUE AT EVERY STEP

In hospital productivity design, every step within every process change should add value to the patients and the financial stability of the hospital. Whether you choose to approach productivity department by department or house-wide, the strategies in “Using Benchmarks: The Good, The Bad, and The Ugly” will guide your productivity transformation process.

To learn more download “Using Benchmarks: The Good, The Bad, and The Ugly.”

RELATED LINKS:

• Hospital Productivity Without Fear 
• Hospital Decisions Today Will Shape Your Hospital’s Future Workforce

About Compass Clinical Consulting
Compass Clinical Consulting helps hospitals reduce the cost of providing safe, quality patient care. Founded in 1979 and based in Cincinnati, OH, Compass has helped hundreds of hospitals and health systems prepare for accreditation, optimize labor cost management, manage clinical resources, and improve patient throughput and physician relations.

Click here to see all recent news from this company

DEURLE, BELGIUM–(Marketwire – November 30, 2010) – Remedent, Inc. (OTCBB: REMI), an international company specializing in research, development and the manufacture of oral care and cosmetic dental products signed an agreement with Small Caps Finance SA to open at least two Glamsmile Studios in Brussels, Belgium and Milan, Italy with an option for Rome, Italy as well.

SCF will provide all the necessary financing to a joint venture between both entities, where Remedent/Glamsmile will be the majority owner and provide all the necessary product and support to open the Studios. Glamsmile will operate and manage the Studios under the same formula for success as it does in Europe and Asia. It is anticipated that both Studios will open prior to the conclusion of our year end, namely March 31, 2011.

“The direct retail model of opening Studios in both Asia and Europe has been the reason for our financial turnaround as opposed to our previous wholesale (B2B) model via a distributor. This has led to two consecutive profitable quarters since the beginning of our financial year, April 1, 2010. In addition to western Europe, we will continue with our Glamsmile Studio expansion in Asia as well where we anticipate opening our Shanghai superstore in early 2011. I am very excited about our new venture with SCF for western Europe which will give us further exposure into two new markets, namely Milan and Brussels. The locations for our two new Studios have already been determined and they will be based in the most affluent shopping areas of both major cities. I look forward to the opening of both these two new locations where we expect the financial success to continue as we have experienced with our other Studios located in both Europe and Asia,” said Guy DeVreesse, the CEO of Remedent.

SCF currently has investments in both the pharmaceutical and health care industries. “The Glamsmile concept is unique and we are very excited about introducing beautiful smiles into new markets,” said Mr. Bernardo Ruzziconi, SCF, Chief Executive Officer.

About Remedent.

Remedent, Inc. specializes in the research, development, manufacturing and marketing of oral care and domestic dentistry products. The company serves the professional dental industry with breakthrough technology for dental veneers. These products are supported by a line of professional veneer whitening and teeth sensitivity solutions. Headquartered in Belgium, Remedent distributes its products to more than 35 countries worldwide. For more information, go to www.remedent.com

Forward-Looking Statements

Statements in the press release that are “forward-looking statements” are based on the current expectations and assumptions that are subject to risks and uncertainties. Such forward-looking statements involve known and unknown risks, uncertainties and other unknown factors that could cause Remedent’s actual operating results to be materially different from any historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements that explicitly describe these risks and uncertainties, readers are urged to consider statements that contain terms such as “believes,” “belief,” “expect”, “intends,” “anticipate,” “anticipates,” “plans,” “projects,” “project,” to be uncertain and forward looking. Actual results could differ materially because of facts such as Remedent’s ability to achieve the synergies and value creation contemplated by the proposed transaction. For further information regarding risks and uncertainties associated with Remedent’s business, please refer to the risks described in Remedent’s filings with the Securities and Exchange Commission, including but not limited to, its annual report on Form 10-K and quarterly reports on Form 10-Q. We undertake no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of the press release.

LOS ANGELES, CA–(Marketwire – November 30, 2010) – MMRGlobal, Inc. (OTCBB: MMRF) (MMR) today announced it has signed a settlement agreement with the Lymphoma Research Foundation (LRF), resolving its lawsuit with LRF and giving the Company exclusive control of certain data and tissue samples created during trials of Favrille, Inc.’s FavId™ vaccine. The assets had been the subject of an ownership dispute with LRF. The Company acquired the FavId intellectual property, along with other biotech assets, from its reverse merger with Favrille, Inc., a San Diego biotech company, in January 2009. More than $140 million was spent on the development of the vaccine and other biotech assets and related patents. 

According to Kathleen M. Smith, a principal at Translational Medicine Consulting and a biorepository expert who provided expert testimony in the MMR litigation with LRF, the tissue samples could have values substantially in excess of one million dollars per set. When combined with clinical data and associated intellectual property belonging to MMR, the values could be significantly greater. 

“We will continue to explore licensing opportunities for these biotech assets, patents and other intellectual property with pharmaceutical companies, universities and institutional investors to create future streams of revenue for our shareholders,” said Robert H. Lorsch, MMRGlobal CEO. “I look forward to these assets being put to use to help find additional treatments for Non-Hodgkin’s Lymphoma and other related diseases while generating licensing revenues to help finance the Company’s primary business, namely the development and distribution of its MyMedicalRecords Personal Health Record and MMRPro Electronic Health Record products and services.”

MMR contended that prior to the merger, portions of the Company’s intellectual property were transferred by previous employees and or consultants of Favrille to third parties, including Lymphoma Research Foundation, without the knowledge and consent of Favrille’s Board of Directors or Science Committee. After MMR learned of the transfer, the Company pursued LRF to regain control of the data and tissue samples on behalf of its shareholders.

As part of the settlement agreement, the Lymphoma Research Foundation also settled a complaint filed in Los Angeles Superior Court by The RHL Group, Inc., a creditor of MMRGlobal, against LRF and others involving the transfer of the data, tissue samples and other assets which previously were the property of Favrille. Although The RHL Group case against LRF is settled, the case against the other named defendants is still active.

Over the last two years, MMRGlobal has been working to maximize the value of its biotech assets by perfecting its worldwide patent portfolio, regaining control of its anti-CD20 antibodies and FavId intellectual property including tissue samples, and developing licensing opportunities for the data and materials for use in Non-Hodgkin’s Lymphoma, target validation and other therapeutic research. As part of the settlement agreement, MMRGlobal shall cause the assets or portions of them to be used in further medical research.

About MMRGlobal, Inc.

MMRGlobal, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc. (“MMR”), provides secure and easy-to-use online Personal Health Records (“PHRs”) and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, financial institutions, and professional organizations and affinity groups. MyMedicalRecords enables individuals and families to access their medical records and other important documents, such as birth certificates, passports, insurance policies and wills, anytime from anywhere using the Internet. The MyMedicalRecords Personal Health Record is built on proprietary, patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user’s account. The Company’s professional offering, MMRPro, is designed to give physicians’ offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients in real time through an integrated patient portal. MMR is an Independent Software Vendor Partner with Kodak to deliver an integrated turnkey EMR solution for healthcare professionals. MMR is also an integrated service provider on Google Health. To learn more about MMRGlobal, Inc. and its products, visit www.mmrglobal.com.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature constitute “forward-looking statements.” Such statements include, but are not limited to, statements regarding MMRGlobal, Inc.’s assets including but not limited to its primary Health IT businesses, samples and data from vaccine and clinical trials, and anti-CD20 antibody assets. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related but not limited to changes in MMRGlobal, Inc.’s business prospects, its results of operations or financial condition, government regulation and changes in healthcare initiatives, developing and defending its intellectual property rights including those pertaining to the Company’s biotechnology assets, the development and approval of biotechnology/biopharmaceutical product candidates and Health IT products and such other additional risks and uncertainties discussed in the Company’s filings with the Securities and Exchange Commission. All subsequent written and oral forward-looking statements attributable to the Company (or any person acting on the Company’s behalf) are qualified by the cautionary statements in this notice. MMRGlobal, Inc. is providing this information as of the date of this release and, except as required by law, does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information.

Click here to see all recent news from this company

RALEIGH, NC–(Marketwire – November 30, 2010) – InoLife Technologies, Inc. (OTCBB: INOL), a service based healthcare products development, integration and marketing Company announced today that it will exhibit at the 18^th Annual World Congress on Anti-aging Medicine and Biomedical Technologies, (A4M) convention held at the Mandalay Bay Convention Center in Las Vegas, Nevada on December 9-11.

“This convention provides an excellent opportunity for our Company to expose our products to the medical community as well as the industry press,” stated Gary Berthold, CEO of InoLife Technologies, Inc. “We at InoLife Technologies would like to invite those health-care professionals that are attending the convention to visit booth 240 to discuss opportunities and for demonstrations of the Company’s DNA-based testing products.” 

InoLife will take advantage of this forum to educate physicians and healthcare practitioners on the advantages and availability of the Company’s Plavix metabolizing test. This DNA-based testing procedure can identify how a patient’s genetic inheritance may affect the body’s response to the popular drug commonly used for patients with cardiovascular risks.

The A4M expects approximately 3000 professionals to attend the convention. It is billed to be the largest and most influential conference and expo worldwide on preventative medicine and bio-medical technologies. The A4M organization is comprised of 22,000-plus members that include physicians, health practitioners, scientists, government officials and members of the general public representing over 105 nations. Eighty-five percent (85%) of the organization’s members are physicians (MD, DO,MBBS) followed by 12% that consists of scientists, researchers, and health practitioners, leaving 3% that are government officials, members of the working press and the general public. 

The A4M is dedicated to educating physicians, scientists and health practitioners on biomedical sciences, breaking technologies and anti aging issues. A4M seeks to disseminate information concerning innovative science and research as well as treatment modalities designed to prolong the human lifespan.

About InoLife Technologies, Inc.
InoLife is poised to become one of the premier U.S. marketers of state-of-the-art DNA-based test products. Positioned for growth and success in a burgeoning market, InoLife Technologies, www.inolifetech.com, is primarily focused on products, services and solutions that will enable state-of-the-art healthcare for today and the future for a diverse base of customers and end users. The Company’s mission is to identify, develop, integrate and bring to market innovative healthcare-based products and services that provide timely and practical solutions. The primary products and services that InoLife is currently addressing focuses upon those specific products and services that provide key solutions through the innovative use of specific DNA testing and Genetic analysis systems.

The principal customers of InoLife’s products and services are healthcare providers, physicians, practitioners, hospitals and outpatient facilities. InoLife will be marketing and distributing its products through traditional distribution channels. Additionally InoLife has developed certain products that can be sold directly to consumers and has created specific programs to reach those customers including e-commerce, direct sales, healthcare providers, pharmacies, distributors, retail sellers and specialty retailers.

TUSTIN, CA–(Marketwire – November 30, 2010) – Radient Pharmaceuticals Corporation (RPC) (NYSE Amex: RPC) announced today the signing of a Letter of Intent (“LOI”) to form an exclusive distribution agreement and collaborative business development partnership with Colombia-based PROCAPS S.A. PROCAPS is a top tier Latin American healthcare distribution company currently commercializing oncology and other therapeutic products throughout countries in Latin America.

RPC and PROCAPS intend to structure a long-term exclusive distribution partnership to build market share and awareness for RPC’s U.S. FDA-cleared Onko-Sure® In Vitro Diagnostic (IVD) cancer test in Latin America. The Companies are working on the following terms:

• RPC and PROCAPS will evaluate strategies to commercialize RPC’s Onko-Sure® IVD cancer test as a medically and economically beneficial cancer test for patients in Colombia and other Latin American healthcare markets.
• PROCAPS will investigate the market opportunity for full-service distribution of RPC’s Onko-Sure® IVD cancer test kit to clinical reference labs, hospitals and cancer treatment centers in designated territories in Latin America.
• RPC will grant PROCAPS first rights for distribution of Onko-Sure® in Colombia, Venezuela, Peru, Ecuador, Bolivia, Panama, Guatemala, Dominican Republic, and El Salvador.

In selecting PROCAPS, RPC acknowledges the Company’s expertise in launching new healthcare products in key Latin American markets. PROCAPS has formed successful partnerships with large pharmaceutical companies including Wyeth, Merck, GSK, and Sanofi. Most recently, PROCAPS has become an exclusive distributor of a US-developed oncology therapeutic.

RPC Chairman and CEO Mr. Douglas MacLellan commented, “Cancer knows no borders, and Radient Pharmaceuticals is well positioned to combat this disease by supplying innovative diagnostic tests like Onko-Sure® on both a domestic and global level. Latin America has an escalating cancer challenge similar to other emerging economies and in working with PROCAPS S.A., RPC holds tremendous commercialization potential for the rapidly expanding Latin American healthcare market. We are eager to finalize our partnership with PROCAPS and begin the marketing and sales of Onko-Sure in this region.”

For additional information on Radient Pharmaceuticals, ADI and its portfolio of products visit the Company’s corporate website at www.Radient-Pharma.com. For Investor Relations information contact Kristine Szarkowitz at [email protected] or 1.206.310.5323.

About Radient Pharmaceuticals:
Headquartered in Tustin, California, Radient Pharmaceuticals is dedicated to saving lives and money for patients and global healthcare systems through the deployment of its FDA-cleared In Vitro Diagnostic Onko-Sure® Test Kits for colon-rectal cancer recurrence monitoring. The company’s focus is on the discovery, development and commercialization of unique high-value diagnostic tests that help physicians answer important clinical questions related to early disease-state detection, treatment strategy and the monitoring of disease progression or recurrence. To learn more about our company, people and potentially life-saving cancer test, visit www.radient-pharma.com.

Forward-Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company’s operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

Click here to see all recent news from this company

CHICAGO, IL–(Marketwire – November 29, 2010) – ForceLogix Technologies Inc. (TSX-V: FLT) is pleased to announce that it filed its interim financial statements and Management’s Discussion and Analysis today for the quarter ended September 30, 2010. The financial statements are available for review on SEDAR, www.sedar.com.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Click here to see all recent news from this company

WESTPORT, CT–(Marketwire – November 29, 2010) – African community groups are transforming the future for orphans and other children affected by HIV and AIDS thanks to U.S.-funded programs, Save the Children said.

“The United States is doing much more than providing lifesaving drug treatment when it comes to helping people around the world battle the AIDS crisis and it must continue to do so,” said Charles MacCormack, President and CEO of Save the Children. “One of the most remarkable changes is the creation of African community networks dedicated to supporting orphans and other children affected by HIV and AIDS.”

“It’s amazing how care and support can replace stigma and isolation when local groups are empowered to mobilize around children who have been orphaned and left vulnerable by HIV and AIDS,” MacCormack said.

More than 17 million children have lost one or both parents to AIDS. Many millions more children have reduced opportunities in life because HIV and AIDS have struck their families and communities. Most of these children are in Africa.

The United States President’s Emergency Plan for AIDS Relief (PEPFAR) has funded programs offering care and support to more than 3.6 million orphans and vulnerable children in Africa. Save the Children has led several of these large programs in Mozambique, Uganda, and Ethiopia and has put special emphasis on empowering local community groups to care for affected children. The result is sustainable change for children.

For World AIDS Day (Dec. 1), Save the Children has released a new multimedia video highlighting new hope for orphans and other children affected by AIDS in Ethiopia, where 530,000 children have benefited from U.S.-funded programs. 

“One of the most interesting changes involves Ethiopia neighborhood associations that originally formed to help poor families cover funeral expenses,” MacCormack said. “Today these groups have transformed to offer new hope to the living. They are helping children get an education, enough to eat, a place to live, and, perhaps most importantly, a renewed sense of community and loving support that they had lost to AIDS.”

See the video and learn how you can help support children affected by HIV and AIDS here:
www.savethechildren.org/worldAIDSday2010

Save the Children is the leading, independent organization that creates lasting change for children in need in the United States and 120 countries around the world.

NEW YORK, NY–(Marketwire – November 29, 2010) – MedLink (OTCBB: MLKNA), a leading provider of health information technology solutions, today announced that it has closed an aggregate of $2.25 million in financing. Aegis Capital Corp, sole placement agent and exclusive investment banker to MedLink, placed $1.0 million through a private placement, and an additional $1.25 million in capital through the sale of convertible notes sold exclusively to institutional investors. The investment capital proceeds will be used to fund increased sales and marketing, working capital needs of the Company, and the acquisition of MedAppz which was announced earlier this month.

“We are extremely pleased to have the support of our investors who affirm our corporate vision, and the overwhelming interest in the offering is a testament to the MedLink team and the cutting edge technology we are providing to the healthcare market,” said Ray Vuono, CEO of MedLink International, Inc. “With this financing, the company is well positioned to deliver its suite of Electronic Health Record (EHR) and Healthcare Information Technology communication platforms, to meet the increasing demand of the industry as healthcare facilities of all sizes are adopting EHR technology to take advantage of the efficiencies and the incentives both on a State and Federal level.”

David Bocchi, Director of Investment Banking at Aegis Capital, said, “MedLink represents a rare and exciting opportunity in a competitive and consolidating space where it continues to demonstrate it has the tools and resources necessary to successfully become an industry leader.” He added, “The management team was instrumental in swiftly securing the capital in a placement with overwhelming investor demand, and we look forward to providing the company with the continued support necessary to assist in its growth.”

About MedLink

MedLink is a healthcare IT company providing the medical community with products and services for the creation, management, and sharing of medical information. The company’s flagship product, MedLink TotalOffice EHR 3.1, a CCHIT Certified® 08 Ambulatory EHR, provides physicians with full EHR and practice management functionality. For more information regarding MedLink’s products and services, please visit www.medlinkus.com.

About Aegis

Aegis Capital is a full-service boutique brokerage operation focused on middle-market corporate finance, research, and valuation services. Aegis actively manages over $2 billion of retail customer assets with over 200 registered representatives in 8 corporate locations. Aegis Capital Corporation was founded in 1984 by Robert Eide, the current CEO and Chairman. Its origins were based on servicing the specific needs of an extremely affluent customer base. For more information, please visit the Aegis website at www.aegiscapcorp.com.

Safe Harbor Statement

This news release may contain forward-looking statements within the meaning of the federal securities laws. Statements regarding future events, developments, the Company’s future performance, as well as management’s expectations, beliefs, intentions, plans, estimates or projections relating to the future are forward-looking statements within the meaning of these laws. These forward-looking statements are subject to a number of risks and uncertainties, outlined in our 2009 Annual Report on Form 10-Kavailable through www.sec.gov. The Company undertakes no obligation to update publicly any forward-looking statement, whether as a result of new information, future events or otherwise.

LOS ANGELES, CA–(Marketwire – November 29, 2010) – Fresh Start Private (OTCQX: CEYY) (PINKSHEETS: CEYY), a leader in the alcohol treatment and rehabilitation industry, today announced that its first facility is operational and able to treat up to 15 patients a day with a potential revenue of $120 Million per year per clinic.

According to the National Institute of Health there are an estimated 17.6 million alcoholics in the USA.

Fresh Start Private’s fully licensed and certified medical facility has three treatment rooms that are each able to process up to five patients per day. As part of the treatment, trained medical doctors insert Fresh Start Private’s exclusively licensed specially formulated biodegradable Naltrexone implant just beneath the skin below the patient’s lower abdominal area.

The FDA approved Naltrexone blocks the part of the brain that “feels” pleasure when patients use alcohol. When these areas of the brain are blocked, patients feel less need to drink alcohol, and they can stop drinking more easily. Once medical intervention has reduced the physical need for alcohol, the program goes on to address the patient’s physiological needs. The combination of these treatments results in sobriety in nearly 100% of all patients.

Fresh Start Private is the only alcohol treatment program to offer a single-administration, long-acting, Naltrexone implant procedure.

 “At Fresh Start Private we have created a comprehensive recovery program that includes state-of-the-art medical intervention, individually tailored Fresh Start Private Coaching Program sessions, rebuilding of family and friend connections and post-treatment continuing care,” stated Dr. Jorge Andrade, CEO of the Company. “Only through a comprehensive treatment solution can a patient have his/her best chance at recovery.”

There are many benefits to the Fresh Start Program compared to other traditional alcohol treatments. As the Fresh Start treatment is administered on an outpatient basis, there is no need for patients to leave their work and family for any extended period of time. In fact, many in treatment return to work the next day and not even co-workers or family members know they are being treated. The Fresh Start team has the experience to handle all alcohol addiction scenarios. The Fresh Start Private program can be less expensive than many traditional treatment centers.

About Fresh Start Private

Fresh Start Private is an alcohol addiction, alcohol withdrawal, alcohol abuse treatment and alcohol detox rehabilitation company on the leading edge of the alcohol addiction treatment. The Company has an exclusive license on a highly effective treatment (Naltrexone Implant) that delivers therapeutic levels of Naltrexone that significantly reduces patients’ cravings for alcohol.

Please visit http://www.freshstartprivate.com.

Statements in this press release may be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “potential,” “up to,” “estimate,” “over,” “intend,” “can be,” “nearly” and similar expressions, as they relate to the company or its management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the company’s business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above and those risks discussed from time to time in Fresh Start filings with the Securities and Exchange Commission. In addition, such statements could be affected by risks and uncertainties related to the ability of Fresh Start to manage product demand, market and customer acceptance, competition, pricing and development difficulties, as well as general industry and market conditions and growth rates and general economic conditions. Any forward-looking statements speak only as of the date on which they are made, and the company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this release. Information on Fresh Start’s website does not constitute a part of this release.

MUNDELEIN, IL–(Marketwire – November 29, 2010) – Medline Industries, Inc., the nation’s largest privately held manufacturer and distributor of healthcare supplies, announced today the signing of a cost-management prime vendor agreement with Cleveland, Ohio-based St. Vincent Charity Medical Center. The five year agreement is anticipated to save the hospital an estimated $2.5 million over the term of the contract.

St. Vincent’s patient-centered focus on quality has earned them the HealthGrades Distinguished Hospital Award for Clinical Excellence for five consecutive years (2006-2010). In keeping with their focus, the hospital plans to take advantage of the many clinical programs Medline offers including the Pressure Ulcer Prevention Program, the Perioperative Pressure Ulcer Prevention Program and the ERASE CAUTI (catheter-associated urinary tract infection) Program. Each of these evidenced-based programs was designed to help improve quality and safety outcomes, increase patient satisfaction and reduce errors for healthcare facilities.

Under the terms of the contract, Medline is expected to generate more than $10 million in annual medical and surgical product sales from the partnership over the term of the agreement. Under the agreement, Medline will provide its broad array of Medline brand medical and surgical products, including surgical procedure trays, patient care products, disposable protective gowns, exam gloves and bandages.

Cost savings and customer service were two key factors in making Medline St. Vincent Charity Medical Center’s prime vendor. Medline will drive cost savings to St. Vincent through delivering Medline manufactured products direct to the healthcare facility from Medline’s newly built 300,000 square foot, state-of-the-art distribution facility in Canton, OH. Medline will also deliver cost savings by reducing distribution fees on other national brand products and product standardization. In addition, Medline will provide enhanced reporting capabilities and offer comprehensive product utilization, education and practical solutions to help the facility control costs and improve patient care. 

About Saint Vincent Charity Hospital
St. Vincent Charity Medical Center is Cleveland’s faith-based, high-quality healthcare provider, with distinguished doctors and caregivers devoted to treating every patient with clinical excellence and compassionate care. St. Vincent Charity Medical Center is home to the renowned Spine and Orthopedic Institute and the Center for Bariatric Surgery. Owned by the Sisters of Charity Health System, St. Vincent Charity Medical Center delivers health for the heart of Cleveland. The Sisters of Charity Health System is a family of hospitals, grant-making foundations, elder care and outreach organizations devoted to healing individual, families and communities. For more information, visit www.stvincentcharity.com.

About Medline Industries, Inc. 
Medline, the nation’s largest privately held manufacturer and distributor of healthcare products, manufactures and distributes more than 100,000 products to hospitals, extended-care facilities, surgery centers, home care dealers and agencies. Headquartered in Mundelein, Ill., Medline has more than 900 dedicated sales representatives nationwide to support its broad product line and cost management services.

Over the past five years, Medline has been the fastest-growing distributor of medical and surgical supplies in the U.S., serving as the primary distributor to over 450 major hospitals and healthcare systems. As a leading distributor, Medline offers a comprehensive array of consulting and management services encompassing the supply chain and logistics, utilization and standardization, business tools and enhanced reporting capabilities and on-staff clinicians.

MONTVALE, NJ–(Marketwire – November 29, 2010) – SRS, the leading provider of productivity-enhancing technology and services for high-performance specialty practices today announced that Indiana Hand to Shoulder Center has selected the SRS Unified Desktop™ for its 35 providers. Indiana Hand to Shoulder Center has 6 office locations providing specialized upper extremity treatment to the greater Indianapolis area.

“The value of an integrated package far exceeds the sum of the benefits of the individual parts,” says James J. Creighton, Jr., M.D., Indiana Hand to Shoulder Center. “Accessing PACS images directly from the patient’s chart in the EMR — without having to open another application and toggle back and forth — will be a huge time-saver for me.”

“The efficiency and ease of use produced by incorporating three vital core technologies into one product is invaluable,” says Audra Frezza, Chief Information Officer, Indiana Hand to Shoulder Center. “One of the reasons we chose SRS is its reputation for the highest levels of customer satisfaction, as well as its drive to stay at the cutting edge of technology. The success level achieved by SRS in the Orthopaedic arena is unparalleled.”

“The Unified Desktop is unique in the EMR industry,” according to Evan Steele, CEO of SRSsoft. “The open architecture upon which our EMR software is built allows us to deliver all clinical and business applications through one seamless user interface. The Unified Desktop is just one of the many ways that SRS boosts productivity for high-performance practices like Indiana Hand to Shoulder Center.”

About SRS
SRS is the leading provider of productivity-enhancing EMR technology and services for high-performance specialty practices — with a successful adoption rate unparalleled in the industry. Offered via the Unified Desktop™, the robust EMR, SRS CareTracker PM, and SRS PACS increase speed, free physicians’ time, boost revenue, and heighten patient care and satisfaction. For more information on SRS, visit www.srssoft.com, e-mail [email protected], fax 201.802.1301, or call 800.288.8369.

About Indiana Hand to Shoulder Center
Indiana Hand to Shoulder Center began in 1971 as a private hand surgery practice. Since then, it has grown to become a renowned center of excellence, recognized across the world for their specialization in problems and injuries of the hand, wrist, elbow and shoulder. Now located on the northwest side of Indianapolis, Indiana Hand to Shoulder Center is the largest free-standing facility of its kind in the world. For more information, visit www.indianahandtoshoulder.com.

OMAHA, NE–(Marketwire – November 29, 2010) – RadTrac, an informatics and biotech solutions firm, has created breakthrough radiation dosage tracking technology that will track and prevent unnecessary radiation exposure for patients and limit liability for hospitals. 

Overexposure to radiation can lead to serious health problems including cancer. There are currently standards set by the American Medical Association for radiation limits but no way exists to track how much cumulative radiation a patient receives. 

Patient radiation levels are tracked and monitored through RadTrac’s proprietary Radiation Dosage Tracking System (RDTS) software engine. Before a patient’s exposure level reaches an unsafe amount, health care providers are alerted and can review diagnostic options before exposing that patient to more radiation, making facilities aware of the potential for overexposure. RDTS allows the physician and medical team to concentrate on practicing medicine and make informed decisions about radiation exposure in real-time.

“The RDTS will not only prevent overexposure and track cumulative exposure, but can also be used as a research tool in the future,” said Gena Kriewald, Co-founder and Vice President of Clinical Development. “The educational benefits that come from creating a national database of radiation exposure on a variety of modalities are immeasurable. By sharing dosage level information across a network of hospitals throughout the nation, facilities can learn not only how to limit exposure but also what modalities are most effective while offering the least amount of radiation.”

“We are currently tracking several facilities with various modalities in regions throughout the United States,” said RadTrac Chief Executive Officer Jesse Fisher. “The RadTrac system takes a proactive approach to preventing radiation exposure by tracking the amount of radiation patients are exposed to — both at the procedure level and cumulatively — and alerting medical professionals before high levels of radiation exposure are reached.”

RadTrac implemented the initial phase of RDTS testing in March of 2010, and completed beta testing in June. The product is now available for release.

About RadTrac: RadTrac is a joint venture of Binovia, Inc., an informatics and biomedical services firm, and Study Overflow Solutions, Inc., (SOS), a teleradiology and practice management firm. RadTrac, a radiology software solutions firm, provides systems and implementation to medical facilities including hospitals, radiology departments and clinics to prevent radiation overexposure and promote x-ray and radiation safety. 

WOBURN, MA–(Marketwire – November 29, 2010) – Yankee Alliance (www.yankeealliance.com), a Group Purchasing Organization for Healthcare industry member organizations, has approved Service Point USA (www.servicepointusa.com) as a vendor for the provision of Large Format Graphics and Signage.

There are 69 YA member organizations which consist of Hospitals and Medical Centers. These are located primarily in the Northeast region of the U.S. where Service Point USA’s service center locations are concentrated.

In addition, YA has thousands of Affiliate Members throughout the U.S. that include Long Term Care Facilities, Clinics, Rehabilitation Facilities, and other Healthcare related businesses. These are potential users of Service Point’s products and services as well.

Member buyers include multiple professionals from each organization in departments of Marketing and Communications, Public Relations, Purchasing, Training and Education, and Facilities Management groups.

Service Point is unique among YA vendors with its specialization in Large Format Graphics, Signage, and Way Finding Systems. Example applications of these products and services for the Healthcare industry include:

• Facility Way / Finding signage systems, interior and exterior
• Educational / Public Relations Displays
• Environmental Graphics / Murals / Posters
• Eco-Friendly Display Graphics
• Information Graphics / HIPAA Communication Posters
• Clean Room / Laboratory moisture-resistant posters and safety signs
• Floor Graphics and Way Finding visual aids
• Event Banners and Flags
• ADA Compliant Signage
• Vehicle Graphics, Vinyl Lettering

YA buyers may send orders and graphic files for production electronically via their unique, online Digital Storefront site established by Service Point for the use of YA members only. Service Point’s Digital Storefront product provides authorized users a secure and efficient means to transmit and store files for future access within a custom branded environment.

The Yankee Alliance agreement augments Service Point USA’s continued pursuit of business within the Healthcare industry, one of its focus markets.

About Service Point
Service Point provides tools and services for greater efficiency in document, print, and information management via networked service centers, online, and through On-Site Services programs with client firms nationwide.

Service Point USA is a subsidiary of Service Point Solutions. It employs 2,400 people across 8 countries through a network of 127 service centers and 794 facilities management programs. SPS is headquartered in Spain and listed on the Madrid and Barcelona stock exchanges (ticker: SPS.MC).

SEATTLE, WA–(Marketwire – November 29, 2010) – With changing consumer expectations and the increased use of mobile devices, healthcare organizations need to find ways to engage members and patients in new ways. But, if achieving behavioral change was as simple as sending a text message, everyone would be eating a healthy diet, exercising regularly and would never smoke.

In this complimentary Webinar, Dr. George Gellert, senior healthcare advisor for Varolii Corporation, and Elizabeth Boehm, principal analyst at Forrester Research, will share insights into how healthcare consumers’ expectations are changing and how healthcare organizations can use mobile devices to engage members and patients in an effective way.

WHEN: Thursday, December 2, 2:00 – 2:45 p.m. ET / 11:00 – 11:45 a.m. PT

WHAT: A complimentary Webinar discussing why patient communications are critical to changing patient behaviors. Attendees will learn:

• How patient preferences impact the effectiveness of communications
• How to improve program adherence with a cross-channel communication strategy
• Why patient communications will be critical to achieving healthier outcomes

WHO: Dr. George Gellert, MD, senior healthcare advisor for Varolii, is a physician epidemiologist and executive with 20 years of experience in health information and communication. Dr. Gellert is the former Chief Medical Officer and EVP for HCORP Inc. and Senior VP of Strategic Alliances at WebMD. 

Elizabeth Boehm, principal analyst at Forrester Research, joined Forrester in 1997 and became co-founder of Forrester’s healthcare and life sciences practice in 1999. She continues to lead the healthcare and life sciences research community, and her own research focuses heavily on the topic areas relevant to healthcare customer experience.

REGISTER: https://www.varolii.com/en/go/2010/smshcwebinar

BURBANK, CA–(Marketwire – November 29, 2010) – Imaging3™, Inc. (OTCBB: IMGG), developer of a breakthrough medical imaging device that produces 3D medical diagnostic images of virtually any part of the human body in real-time, today provided insight into the Company’s strategy for resubmission to the FDA.

“After reviewing with our FDA counsel our prior application, files, images and recent FDA correspondence, Imaging3 plans to resubmit its application for clearance of the Dominion Vi Scanner under the FDA’s 510(k) process,” stated Dean Janes, Chairman and CEO of Imaging3, Inc. According to Mr. Janes, “The results of our review with counsel has determined that the 510(k) program remains the most appropriate and efficient route for FDA approval. It was determined that the ‘De Novo’ and ‘PMA’ processes were not necessary and with some minor adjustments to our existing package along with some additional information and potentially a pre-submission meeting with the FDA, the 510(k) submission should be successful. I am confident that with the assistance of our newly hired FDA consultants and our new strategy we will be able to provide the Agency with a package that meets their needs to expeditiously approve our device,” Mr. Janes added.

About Imaging3
Imaging3, Inc., founded in 1993, is a leading provider of advanced technology medical imaging devices. The Company has developed a breakthrough medical imaging device that produces 3D medical diagnostic images of virtually any part of the human body in real-time. Because these 3D images are instantly constructed in real-time, they can be used for any current or new medical procedures in which multiple frames of reference are required to perform medical procedures on or in the human body. Visit the company’s website at www.imaging3.com

Safe Harbor Statement
Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words “anticipate,” “believe,” “estimate,” “may,” “intend,” “expect” and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to, risks and uncertainties associated with: the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance, the impact on the national and local economies resulting from terrorist actions, and U.S. actions subsequently; and other factors detailed in reports filed by the Company.

MANCHESTER, UNITED KINGDOM–(Marketwire – Nov. 29, 2010) – Bromsgrove based cosmetic surgery provider The Hospital Group, has announced the acquisition of Manchester based cosmetic surgery clinic, SurgiCare, after it bought the company out of administration.

The move secures The Hospital Group as the number one cosmetic surgery provider in Europe, with a network of 27 clinics situated across the UK and Ireland plus over 10 in Spain. The Group also expanded into the USA in 2009 with a base in Los Angeles.

Choosing to retain the SurgiCare brand independently, The Hospital Group and SurgiCare will tackle different areas of the market to gain a complimentary business strategy.

The deal has secured the jobs of 37 workers and follows the group’s recent acquisition of NU Age medical Spa in Newcastle Upon Tyne.

David Ross, Chief Executive at The Hospital Group, said: “This business deal shows the company’s commitment to consolidating and building our position in the UK and international market.

“Many people are struggling to find work in this tough economic climate but this partnership has helped to save jobs as well as open doors and create more opportunities.

“We are really excited about the potential that this opportunity has given us. There will doubtless be synergy and development on both sides.”

The Hospital Group are one of the UK’s leading providers of cosmetic surgery, providing cosmetic, dental and weight-loss solutions for thousands of patients every year. 

Since The Hospital Group was established in 1992, it has grown to become one of the world’s foremost cosmetic and weight loss surgery providers.

The flagship hospital, Dolan Park, is the largest specialist facility of its kind in the UK, dedicated to cosmetic and obesity surgery. All surgeons are GMC registered and cosmetic consultations are performed free of charge, with a lifetime free aftercare package included.

PALO ALTO, CA–(Marketwire – November 28, 2010) – Fovia, Inc., a leader in volume rendering technology, has demonstrated the scalability of its High Definition Volume Rendering® software on the newest generation of Apple® computers. Fovia’s HDVR® software performed 1.5x faster on a Mac Pro 12-core 2.93GHz than it did on a Mac Pro 8-core 2.93GHz (Apple’s previous generation), thereby showcasing perfect, core-for-core scalability. The benchmarking results can be found on Apple’s website at http://www.apple.com/macpro/performance.html.

Fovia’s HDVR algorithms and architecture take full advantage of the future directions in both imaging and computing (larger datasets, larger projection displays, multi-core processors, multi-threading, multi-CPU environments and server-side rendering for thin-clients) without sacrificing quality or performance. This scalability has been, and will continue to be, critical to ensuring the long-term superiority of Fovia’s solution. 

George Buyanovsky, Fovia’s President and C.T.O., remarked, “The highly-efficient multi-core scalability of HDVR has been a major focus of Fovia’s rendering technology. Our CPU-based Volume Ray Casting algorithms very effectively utilize available CPUs resources; therefore, the evolution of general purpose CPUs toward multi-cores and multi-threading are increasingly beneficial for our clients, and we are pleased that our benchmarking results have been published by such a well-respected third party.”

Fovia’s scalable, software-only solution has unparalleled interactive image quality, superior performance, and better memory utilization than other products currently available — including expensive, hardware-based approaches. In addition to its extraordinary scalability with respect to processor performance, Fovia’s HDVR® engine scales with both the exponentially increasing amount of data being generated by modern scanners, and with the continuing growth of larger and higher definition displays now being used for more accurate viewing.

About Fovia, Inc.

Fovia, Inc. was founded in 2003 to address the challenges of data explosion — the exponentially increasing amount of data being acquired by modern imaging modalities. The firm has developed a CPU-based, High Definition Volume Rendering® software solution that leverages and scales with multi-core, multi-processor and multi-threaded generational processor development. Fovia’s HDVR® solution is more scalable, cost effective, flexible, and easily deployable on an enterprise-wide basis than GPU or other hardware-based approaches and can be easily and natively integrated into various original equipment manufacturers’ offerings, therefore allowing OEMs to quickly and cost-effectively offer the world’s most advanced volume rendering to their customers.

For additional information, visit www.fovia.com.

Apple is a registered trademark of Apple Inc.

Fovia, High Definition Volume Rendering and HDVR are registered trademarks of Fovia Inc.

FOSTER CITY, CA–(Marketwire – November 27, 2010) – TeraRecon, Inc. (www.terarecon.com), a global leader in advanced visualization and decision support solutions, has received the North American Growth Leadership of the Year Award in the category of Advanced Visualization and Clinical Applications by the respected independent research firm Frost and Sullivan. This award represents the sixth time in the past 10 years that TeraRecon, Inc. has been recognized with an award from Frost and Sullivan. It is the second time in 2010, following the European Company of the Year Award in the category of Medical Imaging, Advanced Visualization Applications. The full text of the new award can be reviewed on the company’s website at www.terarecon.com/fs2010-2.pdf

The Award is issued contemporaneously with the release of the new Frost and Sullivan market research report on the North American advanced visualization market, and is derived from independent and objective research performed by the Frost and Sullivan team, which was not commissioned or funded by TeraRecon. The research was based on two independent primary research efforts conducted during the last year by Frost & Sullivan researchers, each focused on decision makers for advanced visualization in the United States.

Quoting from the text of the Frost and Sullivan award, “In more than one aspect, TeraRecon has become the leading independent vendor in the North American advanced visualization industry today.” The award noted that TeraRecon is “…capturing a higher market share than all other vendors within its tier of competition” and also recognized the company’s focus on the role and potential of advanced visualization in the healthcare enterprise: “Indeed, TeraRecon’s solutions achieve the highest ratings with regard to their remote access and integration capabilities, making TeraRecon the market leader for delivering advanced visualization enterprise-wide.”

The research also revealed that TeraRecon is perceived as the vendor offering the most advanced technology and the highest performance, that TeraRecon obtained the highest ratings for customer satisfaction, and that the surveyed respondents rated TeraRecon’s solution with the highest ratings for ease of use.

Frost and Sullivan made particular note of iNtuition™ CLOUD, stating “The cloud-based solution launched recently by TeraRecon is yet another illustration of the company’s edge with technology and its ability to react swiftly to emerging industry trends and customer needs.”

Furthermore, the value of the company’s investment in research and development of clinical applications was acknowledged with the observation that “TeraRecon achieved the highest ratings among independent vendors not only from a technology standpoint, but also from a clinical standpoint.”

TeraRecon President & CEO Robert Taylor, Ph.D. commented on the award, “We are truly honored to have received a sixth Frost and Sullivan award — the second within a single year, now recognizing the company’s achievements in the North American market, following up on the recognition we received from Frost and Sullivan earlier in the year relating to our innovative business strategy in Europe. This independent research by Frost and Sullivan objectively proves what we have always strived for relating to our customers’ appreciation of our products’ performance, our customer service, our clinical excellence, and our commitment to enterprise workflow and integration with other informatics systems. The accompanying report also highlights that TeraRecon’s enjoys the highest attachment and integration rate to PACS systems deployed in the North American market, as further evidence of the company’s commitment to a radiologist-centric workflow.”

Dr Taylor continued, “TeraRecon is more committed than ever to innovation and technological and clinical excellence. We are defining new boundaries for advanced visualization every day, as our new iNtuition CLOUD offering gains more and more registered users and the clinical capabilities of iNtuition expands rapidly. We believe that the future of medical imaging will inevitably consist of a combination of on-site software, cloud-based hosting, and meaningful integration with other enterprise healthcare informatics systems, and we embrace this challenge with the greatest enthusiasm and commitment.”

Free evaluation accounts for iNtuition CLOUD can be obtained at terarecon.com/cloud.

About TeraRecon (www.terarecon.com)
TeraRecon is a global leader in advanced image processing, decision support and 3D visualization techniques. The company’s solutions provide advanced imaging support for medical and other visualization applications based on its unique and patented image processing technologies. A six-time winner of Frost and Sullivan awards, the company has developed a leading portfolio of products that advance the performance, quality, functionality, and integration of image processing and 3D visualization systems since its founding in 1997. TeraRecon is a privately held company with headquarters in Foster City, California, USA, European headquarters in Frankfurt, Germany, and branch offices in Concord, Massachusetts, USA and Tokyo, Japan.

About Frost & Sullivan:
Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. The company’s Growth Partnership Service provides the CEO and the CEO’s Growth Team with disciplined research and best practice models to drive the generation, evaluation and implementation of powerful growth strategies. Frost & Sullivan leverages almost 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 31 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com

iNtuition™ is a trademark of TeraRecon, Inc.

ALEXANDRIA, VA–(Marketwire – November 26, 2010) – Mortality rates for people with type 1 diabetes are decreasing, but overall remain seven times higher than those of the general population — likely as a result of long-term complications, a study in the December issue of Diabetes Care reports.

And while there were no significant differences in mortality rates between genders, women with type 1 diabetes were 13 times more likely to die than women who did not have diabetes, reported researchers from the University of Pittsburgh. Also in this study, part of the Epidemiology Research International Study Group, a much higher proportion of African Americans (50.6 percent) died than Caucasians (24 percent).

“It’s unclear why, for both women and African Americans, type 1 diabetes has such a major effect compared to the general population,” said Dr. Trevor Orchard, senior author of the study. “This greater effect of diabetes for women is not seen as strongly in studies in other parts of the world. One thing that is clear is that we need to pay special attention to their care and treatment and continue to investigate why they might be disproportionately impacted by the long-term consequences of this disease.”

Overall, mortality rates for people with type 1 diabetes fell significantly in this community-based population from Allegheny County, PA, over the past several decades, the study found. For those diagnosed between 1965 and 1969, mortality rates were 9.3 times higher than the general population. However, for those most recently diagnosed (1975-1979), the rate was just 5.6 times higher, showing a clear decline.

“It looks like the main improvement in those most recently diagnosed is related to dramatically reducing mortality in the first five years after diagnosis,” said Dr. Aaron Secrest, lead author of the paper. “We think it’s probably a result of better management and awareness of diabetes control, leading to providers and patients doing a better job of monitoring for acute complications.”

Overall, reductions in mortality are most likely due to the tremendous improvements in treatment and care during the 1980s and 1990s, the researchers noted. In particular, blood glucose self-monitoring, A1C testing and use of new blood pressure medications such as angiotensin-converting enzyme inhibitors, which also help protect against diabetic kidney disease. These changes have greatly improved both blood sugar and blood pressure control, often the cause of life-threatening complications.

The study looked at people in Allegheny County the Pittsburgh area who had type 1 diabetes diagnosed as a child between 1965 and 1979 and at the time of analysis had a duration of diabetes between 28 and 43 years, and explored differences in mortality based on sex, race (Caucasian vs. African American) and year of diagnosis.

For more information, please contact Dr. Trevor J. Orchard, University of Pittsburgh, Department of Epidemiology, Graduate School of Public Health, at email: [email protected] or call 412-383-1032.
To contact Dr. Aaron Secrest call 940-597-1991.

Diabetes Care, published by the American Diabetes Association, is the leading peer-reviewed journal of clinical research into one of the nation’s leading causes of death by disease. Diabetes also is a leading cause of heart disease and stroke, as well as the leading cause of adult blindness, kidney failure, and non-traumatic amputations.

The American Diabetes Association is leading the fight to stop diabetes and its deadly consequences and fighting for those affected by diabetes. The Association funds research to prevent, cure and manage diabetes; delivers services to hundreds of communities; provides objective and credible information; and gives voice to those denied their rights because of diabetes. Founded in 1940, our mission is to prevent and cure diabetes and to improve the lives of all people affected by diabetes. For more information please call the American Diabetes Association at 1-800-DIABETES (1-800-342-2383) or visit www.diabetes.org. Information from both these sources is available in English and Spanish.

id=”nav_links”>

VANCOUVER, BRITISH COLUMBIA–(Marketwire – Nov. 26, 2010) – The BC Medical Journal, BC doctors’ flagship medical journal, has completely revitalized its online presence. Beginning today, www.bcmj.org will not only continue with its tight focus on medical stories and advancements that occur in British Columbia, but will be adding the more dynamic qualities that the web is known for. 

BCMJ.org expanded upon its current website, which historically has simply provided the new monthly printed journal in an online method, by also including: 

• Video content linked to clinical articles in the journal that will incorporate related surgical videos and author interviews
• Health Notes for doctors and patients that will provide printable tips to improve your health on topics such as dealing with depression, reducing stress, and dementia, as well as reliable patient information related to clinical articles published in the BCMJ.
• Interactive content such as a blog in which physicians can interact with each other and members of the public and the ability to comment directly on published articles.
• A “people” section focusing on physician authors in the BCMJ, physicians who go above and beyond the call of duty, and stories about physicians’ own experiences in life.

“With the launch of our new website, the BCMJ takes giant leap forward in the brave new world of electronic communication. As the online home of BC physicians, we strive to keep doctors connected while providing them with fresh and relevant medical content,” says the BCMJ’s editor, Dr. David Richardson. 

The new interactive website is open to physicians in BC – and physicians around the globe – as well as all members of the public.

The British Columbia Medical Journal is a general medical journal featuring primarily scientific research, review articles, and updates on contemporary clinical practices written by British Columbian physicians or focused on topics likely to be of interest to them, such as columns from the BC Centre for Disease Control and ICBC. The print BCMJ is issued ten times each year, while bcmj.org will release stories throughout the month. The journal is peer reviewed and edited by an Editorial Board consisting of physicians from varying disciplines. Although it is published by the BC Medical Association (BCMA), it maintains distance from the BCMA in order to encourage open debate. It also hosts an online database for all BCMJ issues dating back to 2000.